



Vaccines and Global Health: The Week in Review
18 September 2021 :: Issue 624
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

Milestones :: Perspectives :: Research

.....
.....

COVID

Editor's Note:

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider them for inclusion in a subsequent edition:

david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a COVID-19 pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

.....
.....

WHO calls on world leaders at the UN General Assembly to focus on vaccine equity, pandemic preparedness, and getting the SDGs back on track

17 September 2021 *News release Geneva*

WHO is urging leaders attending the 76th session of the United Nations General Assembly (UNGA) to guarantee equitable access to COVID-19 vaccines and other life-saving tools; ensure the world is better prepared to respond to future pandemics; and renew efforts to achieve the Sustainable Development Goals (SDGs).

The COVID-19 pandemic has already claimed the lives of nearly 5 million people around the globe, and the virus continues to circulate actively in all regions of the world.

Vaccines are the most critical tool to end the pandemic and save lives and livelihoods. More than 5.7 billion vaccine doses have been administered globally, but **73% of all doses have been administered in just 10 countries. High-income countries have administered 61 times more doses per inhabitant than low-income countries. The longer vaccine inequity persists, the more the virus will keep circulating and evolving, and the longer the social and economic disruption will continue.**

WHO's targets are to vaccinate at least 40% of the population of every country by the end of this year, and 70% by the middle of next year. These targets are achievable if countries and manufacturers make a genuine commitment to vaccine equity.

WHO is calling on countries to fulfil their dose-sharing pledges immediately and to swap their near-term vaccine deliveries with COVAX and AVAT (African COVID-19 Vaccine Acquisition Task Team); WHO is also calling on manufacturers to prioritize supplies to COVAX and partners, and for countries and manufacturers to facilitate the sharing of technology, know-how and intellectual property to support regional vaccine manufacturing.

Even as countries focus on ending this pandemic, the world must also prepare for future pandemics and other health emergencies.

COVID-19 caught the world – including wealthy nations – unprepared for a pandemic of this speed and scale. It hit vulnerable populations particularly hard and exacerbated inequalities.

WHO urges all countries to break the cycle of ‘panic and neglect’ seen after previous health emergencies, and commit adequate financial resources, as well as political will, to strengthening health emergency preparedness across the globe...

.....
.....

Statement by White House Press Secretary Jen Psaki on COVID-19 Summit

September 17, 2021 • *Statements and Releases*

On Wednesday September 22 President Biden will convene a virtual COVID Summit on the margins of the UN General Assembly. This meeting is about expanding and enhancing our shared efforts to defeat COVID-19, building out from previous gatherings of world leaders and ministers in fora like the G7, G20, and Act Accelerator to rally civil society, NGOs, philanthropists, and industry along with world leaders and align on a common vision for defeating COVID-19 together.

We will be asking participants to commit to of a higher level of ambition across four themes:

- :: Vaccinate the World by enhancing equitable access to vaccines and getting shots in arms.
- :: Save Lives Now by solving the oxygen crisis, and making tests, therapeutics and PPE more available.
- :: Build Back Better by establishing a sustainable health security financing mechanism, and global leadership for emerging threats.
- :: Calling the World to Account by aligning around targets, tracking progress, and supporting one another in fulfilling our commitments.

We will have more to share on the COVID Summit in the coming days.

.....
.....

International organizations, vaccine manufacturers agree to intensify cooperation to deliver COVID-19 vaccines

16 September 2021

The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization met with the CEOs of leading vaccine manufacturing companies to discuss strategies to improve access to COVID-19 vaccines, especially in low— and lower middle-income countries and in Africa. **The Task Force expressed concerns that without urgent steps the world is unlikely to achieve the end-2021 target of vaccinating at least 40% of the**

population in all countries — a critical milestone to end the pandemic and for global economic recovery

The Task Force members noted that, despite adequate total global vaccine production in the aggregate, **the doses are not reaching low- and lower middle-income countries in sufficient amounts, resulting in a crisis of vaccine inequity.** The Task Force encouraged countries that have contracted high amounts of vaccine doses, and vaccine manufacturers, to come together in good faith to urgently accelerate COVID-19 vaccine supplies to [COVAX](#) and [AVAT](#), two multilateral mechanisms that are crucial for equitable distribution of vaccines.

Task Force members welcomed the willingness of the CEOs to work collectively with them to end vaccine inequity and their readiness to form a technical working group with the Task Force to exchange and coordinate information on vaccine production and deliveries.

The Task Force stressed that if the 40% coverage threshold is to be reached in all countries by the end of 2021, the following actions need to be taken immediately by governments and vaccine manufacturers:

:: Release doses to low- and lower middle-income countries: Task Force members take note that countries with high vaccination rates have collectively pre-purchased over two billion doses in excess of what is required to fully vaccinate their populations. The Task Force calls again on those countries to urgently:

- i) swap their near-term delivery schedules with COVAX and AVAT,
- ii) fulfill their dose donation pledges with unearmarked upfront deliveries to COVAX, and
- iii) release vaccine companies from options and contracts so those doses can be delivered to people in low- and lower middle-income countries. In addition, vaccine manufacturers should prioritize and fulfill their contracts to COVAX and AVAT.

:: Transparency on supply of vaccines: To ensure that doses reach countries that need them the most, particularly low- and lower middle-income countries, the Task Force calls on vaccine manufacturers to share details on month-by-month delivery schedules for all vaccine shipments, especially for COVAX and AVAT. In its remarks, WHO emphasized its call for a moratorium on booster doses until the end of 2021, with the exception of the immune-compromised, to help optimize supply to low-income countries.

:: Eliminate export restrictions, prohibitions: The Task Force calls on all countries to urgently address export restrictions, high tariffs and customs bottlenecks on COVID-19 vaccines and the raw materials and supplies required for the production and timely distribution of vaccines.

:: Regulatory streamlining and harmonization: The Task Force calls on all regulatory authorities around the world to create regulatory consistency and standardization on the approval of vaccines, and to support the acceptance of the [WHO Emergency Use Listing](#) procedure. In parallel, efforts should be made to boost production of vaccines, diagnostics and treatments globally and expedite equitable delivery of such lifesaving tools to developing countries.

.....
.....

Leaders Make Urgent Call To Accelerate Vaccination Globally And In Africa

14 September 2021 *News release* Geneva

WHO Director-General Dr Tedros Adhanom Ghebreyesus and a group of global health leaders today issued an urgent call for vaccine equity globally and in Africa in particular. The leaders stressed that the worst pandemic in the last hundred years will not end unless and until, there is genuine global cooperation on vaccine supply and access. They also reiterated the WHO's global vaccination target for 70% of the population of all countries to be vaccinated by mid- 2022.

Dr Tedros was joined by Dr Seth Berkley, CEO Gavi, Strive Masiyima, AU Special Envoy for COVID-19, Dr John Nkengasong, Africa CDC Director, Professor Benedict Oramah, President and Chairman of the Board of Directors, Afreximbank, Dr Vera Songwe, UN Under- Secretary- General and Executive Secretary of the Economic Commission For Africa and Dr Matshidiso Moeti, WHO Regional Director for Africa.

The press conference followed two days of meetings among the leaders, with Richard Hatchett, Chief Executive Officer of CEPI joining the meetings as well...

.....
.....

Africa faces 470 million COVID-19 vaccine shortfall in 2021

WHO - Africa Region

16 September 2021

Brazzaville – As the COVAX Facility is forced to slash planned COVID-19 vaccine deliveries to Africa by around 150 million this year, the continent faces almost 500 million doses short of the global year-end target of fully vaccinating 40% of its population. This shortfall comes as Africa tops 8 million COVID-19 cases this week.

With the cutback COVAX is now expected to deliver 470 million doses to Africa this year. These will be enough to vaccinate just 17% of the population, far below the 40% target. An additional 470 million doses are needed to reach the end-year target even if all planned shipments via COVAX, a multilateral initiative aimed at guaranteeing global access to lifesaving COVID-19 vaccines, and the African Union are delivered.

"Export bans and vaccine hoarding have a chokehold on vaccine supplies to Africa. As long as rich countries lock COVAX out of the market, Africa will miss its vaccination goals. The huge gap in vaccine equity is not closing anywhere near fast enough. It is time for vaccine manufacturing countries to open the gates and help protect those facing the greatest risk," said Dr Matshidiso Moeti, World Health Organization (WHO) Regional Director for Africa.

As export bans, challenges in boosting production at COVAX manufacturing sites and delays in filing for regulatory approvals for new vaccines constrain deliveries, COVAX has called for donor countries to share their supply schedules to give more clarity on deliveries.

COVAX has also called for countries with enough vaccines to give up their place in the queue for deliveries. Manufacturers must deliver to COVAX in line with firm commitments, and countries that are well-advanced with vaccinations must expand and accelerate donations, ensuring doses are available in larger, more predictable volumes and with longer shelf lives.

About 95 million more doses are set to arrive in Africa via COVAX throughout September, which will be the largest shipment the continent receives for any month so far. Yet even as deliveries pick up, Africa has been able to fully vaccinate just 50 million people, or 3.6% of its people.

Around 2% of the nearly 6 billion doses given globally have been administered in Africa. The European Union and the United Kingdom have vaccinated over 60% of their people and high-income countries have administered 48 times more doses per person than low-income nations.

"The staggering inequity and severe lag in shipments of vaccines threatens to turn areas in Africa with low vaccination rates into breeding grounds for vaccine-resistant variants. This could end up sending the whole world back to square one," said Dr Moeti...

.....
.....

UNHCR warns of dire consequences for refugees from COVID-19 underfunding

This is a summary of what was said by UNHCR's Chief of Public Health Section, Ann Burton – to whom quoted text may be attributed – at today's press briefing at the Palais des Nations in Geneva.

17 September 2021 |

UNHCR, the UN Refugee Agency, calls for more global attention and funding support, to counter the impact of COVID-19 on forcibly displaced people worldwide.

The COVID-19 emergency tops the list of UNHCR's top-10 underfunded situations in 2021. Only one third of the budgeted requirements of US\$ 924 million has been received, leaving a yawning gap in UNHCR's ability to protect the most vulnerable from the fallout of the pandemic.

Despite progress in many locations where UNHCR is working, we continue to see new cases and people continue to die. While safe and effective vaccines can relieve pressures on health systems and save lives, vaccine inequity continues to hit the hardest in many refugee-hosting states. We know that 86 per cent of refugees are hosted in developing countries. However, some 80 per cent of all vaccine doses have been given in high- and upper middle-income countries.

At the same time, low-income countries, hosting the bulk of the world's refugees, have the least resilient health systems and are struggling to cope with the needs of their own populations – before we add the extra needs posed by hosting refugees. **As UNHCR, we reiterate our call on states to share excess doses with COVAX in a timely way, to address the global vaccine inequity and avoid prolonging the pandemic.**

Until now, we have been very encouraged by the overwhelming response of hosting states in including refugees in the vaccine roll-out and urge them to continue to do so. However, we have seen that many barriers to vaccine access remain. UNHCR stands ready to support states to overcome some of these barriers – provided we have the means to do so – for example, by creating information materials in refugee languages suitable for low literacy levels.

The pandemic hurts forcibly displaced and stateless people in ways that reach far beyond the risk posed by the virus itself. And the failure to adequately fund the response only deepens their plight.

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

Sep 18, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 227M total confirmed cases; 4.7M total confirmed deaths

Global vaccines administered: 5.88B

Number of Countries: 29 [29 week ago]

COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]

COVAX Delivered (Number of Doses): 87M [85M week ago]

Other Delivered (Number of Doses): 130M [110M week ago]

Total Delivered (Number of Doses): 200M [210M week ago]


Total Administered (Number of Doses): 190M [170M week ago]


.....

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

A joint initiative from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **18 Sep 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





.....
.....

World Bank Vaccine Operations Portal

<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>

As of July 29, 2021, the World Bank approved operations to support vaccine rollout in 54 countries amounting to \$4.6 billion. See the latest project financing, project documents and procurement information in the list below:

Countries receiving World Bank support for vaccines

As of September 9, 2021, the **World Bank approved operations to support vaccine rollout in 55 countries amounting to \$4.6 billion. See the latest project financing, project documents and procurement information [in the list here](#).**

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 10 Sep 2021

Confirmed cases ::	226 844 344	[223 022 538 week ago]
Confirmed deaths ::	4 666 334	[4 602 882 week ago]

Vaccine doses administered: 5 634 533 040 [5 352 927 296 week ago]

.....
.....

WHO Director-General's opening remarks at the media briefing on COVID-19 - 14 September 2021

14 September 2021

:: WHO's global targets are to support every country to vaccinate at least 40% of its population by the end of this year, and 70% of the world's population by the middle of next year. So far, just two countries in Africa have reached the 40% target, the lowest of any region. More than 5.7 billion doses have been administered globally, but only 2% of those have been administered in Africa.

:: The longer vaccine inequity persists, the more the virus will keep circulating and changing, the longer the social and economic disruption will continue, and the higher the chances that more variants will emerge that render vaccines less effective.

:: So far, COVAX has shipped more than 260 million doses to 141 countries. But as you know, COVAX has also faced several challenges, with manufacturers prioritizing bilateral deals and many high-income countries tying up the global supply of vaccines.

:: Last year, the African Union established the African COVID-19 Vaccine Acquisition Task Team, or AVAT, as a compliment to COVAX to purchase vaccines for AU Member States. Yesterday and today, we had a very constructive meeting between partners from COVAX and AVAT to agree on a way forward. Vaccine inequity is a solvable problem.

:: This Friday is World Patient Safety Day. Our theme this year is safe maternal and newborn care. Every day, nearly 5,400 babies are stillborn, and more than 800 women and 6,700 newborns die mainly around the time of childbirth. We call on all countries, health workers, communities and partners to act now for safe and respectful childbirth.

.....

Weekly epidemiological update on COVID-19 - 14 September 2021

Overview


With nearly 4 million new cases reported globally in the past week (6-12 September), this represents the first substantial decline in weekly cases in more than two months. All regions reported declines in new cases as compared to the previous week. The number of deaths reported globally in the past week also decreased as compared to the previous week, with just over 62 000 new deaths. The African Region reported an increase in the number of weekly deaths (7%), while the South-East Asia Region reported the largest decrease (20%). The American and Eastern Mediterranean Regions reported slightly smaller decreases, 9% and 6% respectively, while the numbers of deaths reported in the European and the Western Pacific Regions were similar to last week. The cumulative number of cases reported globally is now over 224 million and the cumulative number of deaths is just over 4.6 million.

In this edition, two special focus updates are provided on:

:: SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta which includes updates on the geographic distribution of VOCs

:: COVID-19 in children and adolescents.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 12 September 2021**



**See [Annex 2: Data, table and figure notes](#)

.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 19 August 2021

For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[No updates since 19 Aug 2021]

.....

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - *[Website not responding at inquiry; receiving 403-Forbidden]*

CanSinoBIO

News - *[Website not responding at inquiry]*

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News

September 14, 2021

CureVac Streamlines European Network for mRNA Product Manufacturing

:: CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands
:: Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMA
:: Contracts with manufacturing partners WACKER and Celonic terminated; Rentschler Biopharma and Novartis contracts unaffected

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases - No new digest announcements identified

Moderna

Press Releases

September 16, 2021

Moderna Announces Health Canada Approves its COVID-19 Vaccine

September 15, 2021

Moderna Highlights New Clinical Data on its COVID-19 Vaccine

:: mRNA-1273 remains highly effective against COVID-19 in real-world effectiveness study during surge in Delta cases
:: New analysis of open-label portion of Phase 3 COVE study shows lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after first dose) than participants vaccinated last year (median 13 months after first dose)
:: Company believes data support benefit of an mRNA-1273 booster dose

Novavax

Press Releases

Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S.

Sep 17, 2021

The U.S. Centers for Disease Control and Prevention (CDC) recently provided updated guidance stating that participants in the Novavax PREVENT-19 Phase 3 clinical trial meet the criteria to be considered fully vaccinated two weeks after they have completed the active vaccine series. With this validation from the United States' leading public health authority, Novavax expects our PREVENT-19 Phase 3 clinical trial participants will be considered fully vaccinated and in compliance with mandated vaccination policies, including those of employers and any other organizations or entities requiring proof of vaccination. Novavax is grateful to our clinical trial participants for helping to ensure a safer future for all, and we continue to advocate for them at the highest levels.

Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents

Sep 16, 2021

- Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
- Will assess potential for flexibility in the delivery of COVID-19 vaccines

Pfizer

Recent Press Releases

FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations

09.17.2021

:: Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants

:: Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series

:: Real-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country's vaccine rollout

:: FDA expected to make its decision in the coming days

Sanofi Pasteur

Press Releases

September 14 2021 *Press releases*

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company's efforts to develop transformative vaccines and therapies using mRNA technology. The acquisition adds a critical pillar to the company's mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases...

Serum Institute of India

NEWS & ANNOUNCEMENTS

Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance

:: BBL will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets

:: SILS to receive ~15% stake in BBL at a post-money valuation of ~\$4.9 billion

Bengaluru, Karnataka, India – September 16, 2021 Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. today announced a strategic alliance.

Under the terms of the agreement, BBL will offer approximately 15% stake to SILS, at a post-money valuation of ~\$4.9 billion, for which it will get committed access to a 100 million doses of vaccines per annum for 15 years, primarily from SILS's upcoming vaccine facility in Pune with commercialization rights of the SILS vaccine portfolio (including COVID-19 vaccines) for global markets...

Sinopharm/WIBPBIBP

News - [Website not responding at inquiry]

Sinovac

Press Releases

SINOVAC agrees to supply an additional 101,000 doses of COVID-19 vaccines (CoronaVac®) to meet demand for inactivated virus vaccines from Singapore residents

2021/09/15

- Doses will be available through SGX-Catalist listed Livingstone Health group at 17 clinics islandwide
- Inactivated viral vaccines offer an alternative option for those unable to take up vaccines available under the National Vaccine Programme, or prefer inactivated virus vaccines

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

SK Biosciences

Press releases - No new digest announcements identified

.....

.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 18 Sep 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week's edition]



24

vaccines approved for use by at least one national regulatory authority ¹



7

vaccines in WHO's Emergency Use Listing



18.7bn

doses secured globally



\$2-\$37

reported vaccine price range per dose



5.09bn

doses COVAX has secured, optioned, or received as donations



281.1M

doses shipped through COVAX to 141 countries

No new bilateral deals reported.

.....

.....

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

.....
.....


Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 18 Sep 2021]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)






■■■■■
■■■■■

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 18 Sep 2021]

- [42.9%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- [5.88 billion doses](#) have been administered globally, and [29.49 million](#) are now administered each day.
- Only [1.9%](#) of people in low-income countries have received at least one dose.




Daily COVID-19 vaccine doses administered per 100 people, Sep 17, 2021

Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.



[LINEAR](#) [LOG](#) [+ Add country](#)



Source: Official data collated by Our World in Data - Last updated 18 September 2021, 08:10 (London time)

OurWorldInData.org/coronavirus • CC BY


Dec 2, 2020 Sep 17, 2021

COVID-19 vaccine doses administered per 100 people, Sep 17, 2021

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.



[LINEAR](#) [LOG](#) [+ Add country](#)



Source: Official data collated by Our World in Data - Last updated 18 September 2021, 08:10 (London time)
OurWorldInData.org/coronavirus • CC BY

Dec 1, 2020 Sep 17, 2021

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

CDC - ACIP

Next ACIP Meetings

:: September 22, 2021, 10:00 a.m. – 5:00 p.m. and September 23, 2021, 11:00 a.m. – 2:00 p.m. is a virtual COVID-19 meeting at <https://video.ibm.com/channel/VWBXKBR8af4> *No registration is required to watch the webcast.*

No Agenda posted at 18 Sep 2021.

.....

Vaccines and Related Biological Products Advisory Committee- FDA

:: Vaccines and Related Biological Products Advisory Committee September 17, 2021

Agenda

The committee met in open session to discuss the Pfizer-BioNTech supplemental Biologics License Application for COMIRNATY for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, in individuals 16 years of age and older.

YouTube recording: <https://youtu.be/WFph7-6t34M>

Editor’s Note:

No FDA announcement on action proceeding from this meeting was identified at 18 Sep 2021 - 1600/New York. We include the Pfizer announcement and coverage from the *New York Times* below for context:

FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations

09.17.2021

:: Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants

:: Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series

:: Real-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout

:: FDA expected to make its decision in the coming days

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA...

[An FDA panel's vote deals the Biden administration's push for universal booster shots a setback.](#)

New York Times, 17 Sep 2021

The Biden administration's push to make Covid-19 booster shots available to most fully vaccinated adults has been stymied for now by a Food and Drug Administration advisory panel's recommendation that Pfizer boosters be made available only to those 65 and over and those at high risk of severe Covid. However, the roiling debate over whether the shots are needed more broadly remains unsettled.

The panel of experts on Friday overwhelmingly voted not to recommend boosters for those over 16 after a tense, daylong debate that put divisions within the agency and the administration on public display.

The vote was a blow to President Biden, strengthening criticism of his effort to enhance the immunity of already vaccinated Americans at a time when most residents of poor nations have not even had first doses. The F.D.A. and the Centers for Disease Control and Prevention authorized third shots for some immunocompromised individuals more than a month ago, on the ground that the additional dose would simply lift their protection to the level other people achieve with two shots.

Some F.D.A. experts said that the data from Pfizer and elsewhere still seemed to show that two shots protected against severe disease or hospitalization for months afterward, and that there was not enough evidence that a third shot would stem the spread of infection. Some also criticized a lack of data that an additional injection would be safe for younger people.

The panel's final recommendations left some room for the White House to argue that the core of its booster strategy remained intact. Depending on how "at high risk" is defined, tens of millions of Americans could conceivably be deemed eligible for additional shots of the Pfizer vaccine. And a small but growing number of people have stopped waiting for federal authorization and are finding ways to receive booster shots...

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

September 17, 2021 • Press Briefings

[Statement by White House Press Secretary Jen Psaki on COVID-19 Summit](#)

September 17, 2021 • Statements and Releases

[See Milestones above for detail]

[Executive Order on Adding Measles to the List of Quarantinable Communicable Diseases](#)

September 17, 2021 • Presidential Actions

[Remarks by President Biden at a Meeting with Business Leaders and CEOs on the COVID-19 Response](#)

September 15, 2021 • Speeches and Remarks

.....

.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 13-16 September 2021](#)

News 17/09/2021

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

No new digest content identified

.....



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
78.3%	71.8%

Data as of 2021-09-17

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 17 September 2021

[Commissioner Lenarčič visits Haiti as EU Humanitarian Air Bridge flight reaches the country](#)

In the context of the continued EU support following the devastating earthquake that hit Haiti on 14 August, Commissioner for Crisis Management Janez Lenarčič is travelling to Haiti today.

Press release 16 September 2021

[European Commission announces the New European Bauhaus prize winners](#)

Today, the Commission announced the 20 winners of the 'New European Bauhaus Awards' and the 'New European Bauhaus Rising Stars'.

[New European Bauhaus website](#)

Press release 15 September 2021


New European Bauhaus: new actions and funding to link sustainability to style and inclusion

Today, the Commission adopts a Communication setting out the concept of the New European Bauhaus.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

[See Africa announcements in Milestones above]



Current at 09/01/2021 Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

The single-component Sputnik Light vaccine authorized in Iran

Press release, 15.09.2021

Sputnik V demonstrates 97.2% efficacy and high safety profile against COVID during the vaccination campaign in Belarus

Press release, 15.09.2021

Study on Sputnik Light (first component of Sputnik V) vaccine's efficacy among the elderly in Argentina published in EClinicalMedicine journal

Press release, 13.09.2021

.....

.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
18 September 2021,
08:00 IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (1.02%)

340639 (1583↑)

Discharged (97.65%)

32632222 (33798↑)

Deaths (1.33%)

444529 (281↑)

COVID-19 Vaccination
as on : 18 September
2021, 08:00 IST
(GMT+5:30)

Total Vaccination : 79,53,09,089 (2,26,19,002↑)

Latest Updates

No new digest content identified

Government of India – Press Information Bureau

Latest Press Releases

No new digest content identified

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified

.....

.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

China surpasses 1 billion fully vaccinated

2021-09-17

China's Chongqing to vaccinate foreign minors against COVID-19

2021-09-17

HONGQING -- Southwest China's Chongqing Municipality will administer COVID-19 vaccines to foreigners aged 12 to 17 from Saturday on a voluntary basis, according to the Chongqing Foreign Affairs Office.

Foreign citizens who are covered by the local health insurance program will enjoy the same policy as insured Chinese people, and those not covered will be charged 100 yuan (about 15.5 U.S. dollars) per dose.

The vaccines are domestically-developed inactivated COVID-19 vaccines, and a total of one or two doses may be required subject to different vaccines...

.....

.....

.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 15 September 2021

:: GPEI announced a series of commitments to advance gender equality at the Generation Equality Forum in Paris, organized by UN Women and hosted by the Governments of France and Mexico between June 30 and July 2, 2021. The Forum kickstarted a 5-year journey to accelerate ambitious action and implementation on global gender equality. Read more

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

:: Pakistan: three cVDPV2 positive environmental samples

:: Nigeria: 10 cVDPV2 cases

:: Mali: 1 cVDPV2 case

.....

.....

WHO/OCHA Emergencies

Editor's Note:

WHO has apparently reorganized and fundamentally shifted how it judges and tracks "emergencies". We found no announcement of descriptive information to share and present the webpage structure as

encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Crisis in Tigray, Ethiopia](#) *[Last apparent update: 5 Aug 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Coronavirus disease \(COVID-19\) pandemic](#) *[See COVID above]*

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) *[Last apparent update: 24 July 2018]*

[Yemen crisis](#) *[Last apparent update: 12 February 2021]*

[Syria crisis](#) *[Last apparent update: 18 June 2021]*

[Somalia crisis](#) *[Last apparent update: 24 March 2018]*

[Nigeria crisis](#) *[Last apparent update: 9 May 2018]*

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) *[Last apparent update: 17 Aug 2021]*

[Zika virus disease outbreak, 2015-2016](#) *[Last apparent update: 24 Jan 2020]*

[Ebola outbreak: West Africa, 2014-2016](#) *[Last apparent update: 17 Aug 2021]*

[Iraq crisis](#) *[Last apparent update: 9 Jan 2008]*

[South Sudan crisis](#) *[Last apparent update: 23 Sep 2020]*

[Avian influenza A \(H7N9\) virus outbreak](#)

:: 13 September 2021 *News release*

Upcoming WHO Consultation on the Composition of Influenza Virus Vaccines for the Southern Hemisphere 2022

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) *[Last apparent update: 10 Aug 2010]*

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Afghanistan

[Afghanistan: Weekly Humanitarian Update \(6 – 12 September 2021\)](#)

Northern Ethiopia

No new digest content identified

.....

.....

WHO & Regional Offices [to 18 Sep 2021]

<https://www.who.int/>

17 September 2021

News release

[WHO calls on world leaders at the UN General Assembly to focus on vaccine equity, pandemic preparedness, and getting the SDGs back on track](#)

17 September 2021

Departmental news

[Improving oral health through use of digital technology](#)

16 September 2021

Joint News Release

[WHO/ILO: Almost 2 million people die from work-related causes each year](#)

16 September 2021

Joint News Release

[International Organizations, Vaccine Manufacturers Agree to Intensify Cooperation to Deliver COVID-19 Vaccines](#)

16 September 2021

Departmental news

[WHO's World Patient Safety Day Goals 2021 promote safe maternal and newborn practices](#)

16 September 2021

Departmental news

[Global community of practice grows to over 500 WHO trained infodemic managers](#)

14 September 2021

News release

[Leaders Make Urgent Call To Accelerate Vaccination Globally And In Africa](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

- :: Towards Africa's first mRNA vaccine technology transfer hub 18 September 2021
- :: Raising faith in COVID-19 vaccines in Lesotho 17 September 2021
- :: Cameroon's community leaders drive demand for COVID-19 vaccines 17 September 2021
- :: Africa faces 470 million COVID-19 vaccine shortfall in 2021 16 September 2021
- :: Sierra Leone receives 113,490 Pfizer vaccines donated by the US Government via COVAX Facility 13 September 2021

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

- :: 13 September 2021 News release Countries in WHO South-East Asia Region endorse health promoting schools, safe school operations during pandemic

WHO European Region EURO

- :: Investing in and protecting the health workforce: progress at RC71 17-09-2021
- :: World Patient Safety Day shines a spotlight on maternal and newborn health 17-09-2021
- :: Recovering from alcohol addiction in prison: Bruce shares his story 16-09-2021
- :: Highlights from the 71st session of the WHO Regional Committee for Europe 16-09-2021
- :: Side event for ministers shows why behavioural and cultural insights matter 16-09-2021

WHO Eastern Mediterranean Region EMRO

- :: Creating a safe environment for mothers and newborns in Somalia 16 September 2021

WHO Western Pacific Region

No new digest content identified

.....

New WHO Publications [Selected]

<https://www.who.int/publications/i>

Selected Titles

15 September 2021

[Frequently asked questions: COVID-19 vaccines and breastfeeding based on WHO interim recommendations,...](#)

Financing common goods for health

14 September 2021 :: 44 pages

WHO | Guidance (normative)

Overview

Common Goods for Health (CGH) are the core population-based functions or interventions that are essential to the health and well-being of entire societies. They necessitate public financing and public

action as they are public goods or have large social externalities, and thus will not arise through market forces alone.

The objectives of this guidance document are to clearly define CGH, to connect CGH with other critical health agendas to build more responsive and resilient health systems and to address challenges to financing and prioritizing CGH at national, sub-national and community levels. This document delineates the relevant CGH categories, sub-categories and functions, which can aid in policy discussions, budget dialogues (including prioritization processes in countries) and health expenditure tracking processes as means of monitoring and accountability.

PDF: <https://apps.who.int/iris/rest/bitstreams/1369621/retrieve>

[Excerpt]

Box 3. Common goods for health and vaccination

There are aspects of vaccinations that fall squarely under the category of CGH. Several critical CGH functions that support vaccination efforts include: research and development, surveillance, community engagement and public information campaigns, safety and quality regulations and protocols and overall vaccination policies. But vaccinations also entails components of market-based demand, in that individuals are willing to pay for vaccination for themselves or their family members.

The specific argument for the collective, public financing for vaccination is based on the presence of large social externalities, similar to services aimed at reducing the spread of communicable diseases. In the case of vaccinations, it is important to clearly define what these externalities are. A key distinction is *whether the vaccine only benefits the individual* (such as rabies vaccinations or any vaccine that would only protect the individual from the serious effects of a pathogen while not stopping transmission), or *whether the vaccine protects from transmission* in addition to protecting the individual (such as the measles vaccine). The effects of the latter impacts a larger population than the protected individual.

Within vaccination there is a threshold at which a critical mass of individuals in a society have been immunized and consequently protect individuals who are not immunized. Until this point of “herd immunity” (23) the benefits of vaccination primarily accrue to the individual and the people that the individual comes into contact with. A key policy intervention for public action is for the state to take action to identify and fill the gap between the demand for vaccination and the threshold needed to achieve herd immunity. In this way, the societal externalities provided by herd immunity fully justifies public financing for certain types of vaccine cold supply chain and subsidies to remove financial barriers to access.

.....
.....

CDC/ACIP [U.S.] [to 18 Sep 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

CDC to Invest \$2.1 Billion to Protect Patients and Healthcare Workers from COVID-19 and Future Infectious Diseases

Friday, September 17, 2021

Today, the Biden-Harris Administration announced a \$2.1 billion investment to improve infection prevention and control activities across the U.S. public health and healthcare sectors. The Biden-Harris Administration, working through the Centers for Disease Control and Prevention (CDC), is investing

American Rescue Plan funding to strengthen and equip state, local, and territorial public health departments and other partner organizations with the resources needed to better fight infections in U.S. healthcare facilities, including COVID-19 and other known and emerging infectious diseases.

The funding announced today is a commitment that will allow the United States to expand public health and improve the quality of healthcare in our country, including addressing healthcare-related inequities. It will assist healthcare personnel to prevent infections more effectively in healthcare settings, support rapid response to detect and contain infectious organisms, enhance laboratory capacity, and engage in innovation targeted at combating infectious disease threats. Improvements in infection prevention will span the healthcare continuum, including 6,000 hospitals, 15,400 nursing homes and other long-term care facilities, 7,900 dialysis clinics, and 4,700 ambulatory surgery centers, and will extend to other outpatient settings.

"This funding will dramatically improve the safety and quality of the healthcare delivered in the United States during the pandemic and in the future," said CDC Director Rochelle P. Walensky, M.D., M.P.H. "Funding will provide significant resources to our public health departments and healthcare systems and opportunities to develop innovative strategies to protect every segment of the U.S. population, especially those disproportionately affected by the pandemic, at a time that they are hit hard." Additionally, these investments will help address the rise of healthcare-associated infections, which increased as U.S. hospitals were inundated by COVID-19—reversing national progress seen prior to the pandemic.

Over the next 3 years, CDC will issue \$1.25 billion of the total to 64 state, local, and territorial health departments to support this work. Initial awards totaling \$885 million will be made in October 2021 to these jurisdictional health departments. CDC will use the majority of this initial funding in October, \$500 million, to support a new force in the fight against COVID-19 to protect our most disproportionately affected population...

Next ACIP Meetings

No registration is required to watch the webcast.

:: September 22, 2021, 10:00 a.m. – 5:00 p.m. and September 23, 2021, 11:00 a.m. – 2:00 p.m. is a virtual COVID-19 meeting at <https://video.ibm.com/channel/VWBXKBR8af4>
No Agenda posted at inquiry.

:: September 29, 2021, 10:00 a.m. – 5:30 p.m. virtual meeting at

<https://video.ibm.com/channel/VWBXKBR8af4>

Agenda draft: https://www.cdc.gov/vaccines/acip/meetings/downloads/agenda-archive/Draft_Meeting-Agenda_Sept-29-2021_for-posting-508.pdf

MMWR News Synopsis Friday, September 17, 2021

:: Disaggregating Data to Measure Racial Disparities in COVID-19 Outcomes and Guide Community Response — Hawaii, March 1, 2020–February 28, 2021

:: Longitudinal Trends in Body Mass Index Before and During the COVID-19 Pandemic Among Persons Aged 2–19 Years — United States, 2018–2020

:: Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021

:: Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021
:: Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021
:: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 25 announcements/reports/data summaries.

:: EARLY RELEASE: Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
9/17/2021

.....

.....

Africa CDC [to 18 Sep 2021]

<http://www.africacdc.org/>

News

Press Releases

African Union and EDCTP sign Memorandum of Understanding to promote new paradigm in health

ADDIS ABABA, ETHIOPIA, and THE HAGUE, THE NETHERLANDS, September 14, 2021 – The African Union (AU) through the African Centres for Disease Control and Prevention (Africa CDC), and the European and Developing Countries Clinical Trials Partnership (EDCTP) have signed a Memorandum of Understanding (MoU) aimed at establishing a framework to serve as a firm basis for cooperation in their shared goals to promote a new paradigm in health.

Through the MoU, the Africa CDC and EDCTP express their commitment towards joining efforts and maintaining a close and continuous relationship for the achievement of their common objectives. The scope of the MoU is defined through the following themes: Emerging and re-emerging infectious diseases, epidemic intelligence and capacity building for preparedness and outbreak response. The MoU also covers implementation and public health research, the one health approach, and data management. AU and EDCTP will cooperate to implement a programme of work for the execution of activities within these themes.

“The COVID-19 pandemic represents an unprecedented challenge to health systems, the economy and society across Africa. The partnership between Africa CDC and EDCTP will allow African Union Member States to build back better and stronger from the pandemic. It will take Member States a step closer to a strong and resilient health systems that can prevent, detect, and efficiently respond to infectious disease threats, wherever and whenever they may occur on the continent.” Dr John Nkengasong, Director of Africa CDC...

.....

.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 18 Sep 2021]

<http://en.nhc.gov.cn/>

News

Sept 18: Daily briefing on novel coronavirus cases in China

On Sept 17, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 46 new cases of confirmed infections.

China surpasses 1 billion fully vaccinated

2021-09-17

China's Chongqing to vaccinate foreign minors against COVID-19

2021-09-17

HONGQING -- Southwest China's Chongqing Municipality will administer COVID-19 vaccines to foreigners aged 12 to 17 from Saturday on a voluntary basis, according to the Chongqing Foreign Affairs Office.

Foreign citizens who are covered by the local health insurance program will enjoy the same policy as insured Chinese people, and those not covered will be charged 100 yuan (about 15.5 U.S. dollars) per dose.

The vaccines are domestically-developed inactivated COVID-19 vaccines, and a total of one or two doses may be required subject to different vaccines...

National Medical Products Administration – PRC [to 18 Sep 2021]

<http://english.nmpa.gov.cn/news.html>

News

Over 2.16b doses of COVID-19 vaccines administered in China

2021-09-18

More than 2.16 billion doses of COVID-19 vaccines had been administered in China as of Thursday, data from the National Health Commission showed on Sept 17.

Premier Li stresses professional ethics among medical workers

2021-09-15

Premier Li Keqiang, also a member of the Standing Committee of the Political Bureau of the Communist Party of China Central Committee, presided over a medical expert symposium and listened to the attendees' opinions and suggestions on the development and innovation of medical and health services during a visit to the Peking Union Medical College Hospital on Sept 13.

CCDC Weekly - Weekly Reports: Current Volume (3)

2021-09-17 / No. 38

[PDF of this issue](#)

:: Preplanned Studies: Outbreaks of Acute Respiratory Disease Associated with Human Adenovirus Infection in Closed Camps, China, December 2011–March 2014

:: Preplanned Studies: Malaria Surveillance of Entry People During the COVID-19 Epidemic — Guangdong Province, China, October 2020–May 2021

:: Preplanned Studies: Identifying the Key Nodes of HIV Molecular Transmission Network Among Men Who Have Sex with Men — Guangzhou, Guangdong Province, China, 2015–2017

:: Notes from the Field: Two Confirmed Patients of Anthrax — Binzhou City, Shandong Province, China, August 2021

:: Notes from the Field: HIV-2 Seroepidemiological Evidence in Hunan Province — China, 2003–2020

.....
.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 18 Sep 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 18 Sep 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 18 Sep 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

[Gates Foundation's Annual Goalkeepers Report Finds Stark Disparities in COVID-19 Impacts](#)

New data reveals world stepped up to prevent worst-case scenarios from happening; spotlights need for long-term investments to ensure an equitable recovery and continued progress toward the Global Goals

SEATTLE (September 13, 2021) — The Bill & Melinda Gates Foundation today launched its fifth annual Goalkeepers Report, featuring an updated global dataset illustrating the pandemic's adverse impact on progress toward the United Nations Sustainable Development Goals (Global Goals). This year's report, co-authored by Bill Gates and Melinda French Gates, co-chairs of the Bill & Melinda Gates Foundation, shows that disparities caused by COVID-19 remain stark, and those who have been hardest hit by the pandemic will be the slowest to recover. Because of COVID-19, an additional 31 million people were pushed into extreme poverty in 2020 compared to 2019. And while 90% of advanced economies will regain pre-pandemic per capita income levels by next year, only a third of low- and middle-income economies are expected to do so...

Bill & Melinda Gates Medical Research Institute [to 18 Sep 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 18 Sep 2021]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 18 Sep 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – September 2021*** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 18 Sep 2021]

<http://cepi.net/>

Latest News

[Two expert health leaders join CEPI Board](#)

September 16, 2021, Oslo, Norway– World-leading health experts Dr. Nísia Trindade Lima and Dr. Juan Pablo Uribe have been appointed to the Board of the Coalition for Epidemic Preparedness Innovations (CEPI), an international organisation working to rapidly advance vaccines against COVID-19 and other emerging infectious diseases, and enable access to these vaccines for people during outbreaks...

DARPA – Defense Advanced Research Projects Agency [to 18 Sep 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 18 Sep 2021]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 18 Sep 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,

tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

14 September 2021

[African Union and EDCTP sign Memorandum of Understanding to promote new paradigm in health](#)

The African Union (AU) through the African Centres for Disease Control and Prevention (Africa CDC), and the European and Developing Countries Clinical Trials Partnership (EDCTP) have signed a Memorandum of Understanding (MoU) aimed at establishing a framework to serve as a firm basis for cooperation in their shared goals to promote a new paradigm in health.

Through the MoU, the Africa CDC and EDCTP express their commitment towards joining efforts and maintaining a close and continuous relationship for the achievement of their common objectives. The scope of the MoU is defined through the following themes: Emerging and re-emerging infectious diseases, epidemic intelligence and capacity building for preparedness and outbreak response. The MoU also covers implementation and public health research, the one health approach, and data management. AU and EDCTP will cooperate to implement a programme of work for the execution of activities within these themes...

Emory Vaccine Center [to 18 Sep 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 18 Sep 2021]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

Fondation Merieux [to 18 Sep 2021]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 18 Sep 2021]

<https://www.gavi.org/>

13 September 2021

[Iraq receives first doses donated by Italy through COVAX](#)

GHIT Fund [to 18 Sep 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that

No new digest content identified.

Global Fund [to 18 Sep 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 18 Sep 2021]

<https://www.glopid-r.org/news/>

No new digest content identified.

Hilleman Laboratories [to 18 Sep 2021]

<http://www.hillemanlabs.org/>

Website reports "under maintenance" at inquiry

Human Vaccines Project [to 18 Sep 2021]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Sep 16, 2021

[Flor Munoz: What is Driving a Surge in COVID Cases Among Children?](#)

IAVI [to 18 Sep 2021]

<https://www.iavi.org/newsroom>

Latest News

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 18 Sep 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

[President Peter Maurer addresses the High-level Ministerial Meeting on the Humanitarian Situation in Afghanistan](#)

Secretary-General Guterres, Excellencies, I have just returned from Afghanistan, where I met with the Taliban leadership and visited ICRC's humanitarian operations, which have continued largely uninterrupted. Across the country, the magnitude of need i

13-09-2021 | Statement

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 18 Sep 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

[More than 139 million people hit by climate crisis and COVID-19, new IFRC analysis reveals](#)

13/09/2021

[WHO/Europe and IFRC sign Memorandum of Understanding to help countries achieve health for all](#)

13/09/2021

Institut Pasteur [to 18 Sep 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 18 Sep 2021]

<http://www.iom.int/press-room/press-releases>

News - Selected

No new digest content identified.

ISC / International Science Council [to 18 Sep 2021]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News

Blog

[How can we communicate science in a more inclusive and accessible manner?](#)

17.09.2021

As part of the continuous workshop series by and for the ISC Science Communications Network, we gathered for an interactive session to discuss best practices in accessible and inclusive science communication. Watch the recordings, download the slides, and connect with the speakers...

IVAC [to 18 Sep 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events
No new digest content identified.

IVI [to 18 Sep 2021]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

[IVI's 20th International Vaccinology Course brings virtual training to vaccine professionals and students across 155 countries](#)

Johns Hopkins Center for Health Security [to 18 Sep 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

[New Local Research Reports Released on Carrying Equity in COVID-19 Vaccination Forward](#)

September 15, 2021

The CommuniVax Coalition, which is led by the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health and the Department of Anthropology at Texas State University, released 4 new local reports that share findings from local rapid research within Black and Hispanic/Latino communities in Alabama, California, Idaho, and Maryland.

The new reports, produced by the local CommuniVax teams, highlight the urgent need to humanize delivery and communication strategies for COVID-19 vaccines, develop better and heterogenous messaging, and anchor COVID-19 vaccination efforts in hard-hit communities in a holistic "whole person" recovery process...

MSF/Médecins Sans Frontières [to 18 Sep 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

Coronavirus COVID-19 pandemic

[European Union: more empty promises about global COVID-19 vaccine equity](#)

Project Update 15 Sep 2021

Niger

[Combating malaria through water treatment for communities in Niger](#)

Project Update 14 Sep 2021

... "The EU likes to portray itself as a champion of vaccine equity," says Dr Christos Christou, president of Médecins Sans Frontières. "But the gap between those beautiful words and its actions is embarrassingly wide..."

National Academy of Medicine - USA [to 18 Sep 2021]

<https://nam.edu/programs/>

Selected News/Programs

[Risa Lavizzo-Mourey Receives Lienhard Award; Spero M. Manson Receives Sarnat Prize](#)

September 15, 2021

Risa Lavizzo-Mourey Receives Lienhard Award From National Academy of Medicine for Leadership to Improve the Health of All Americans The National Academy of Medicine today announced Risa Lavizzo-Mourey is the recipient of the 2021 Gustav O. Lienhard Award for Advancement of Health Care for her unwavering efforts to improve the health of all Americans by [...]

New Discussion Paper Urges Health Care Quality and Safety Initiatives to Center Health Equity

September 15, 2021

A new individually authored discussion paper in NAM Perspectives — the digital periodical of the National Academy of Medicine — published September 15, 2021 identifies health equity as the area of most urgent and cross-cutting concern for health care quality organizations and outlines a proposed agenda for centering equity in efforts moving forward. On the [...]

National Academy of Medicine Announces 10 Emerging Leaders in Health and Medicine

September 14, 2021

The National Academy of Medicine (NAM) today announced the 2021 Emerging Leaders in Health and Medicine Scholars. These individuals are early- to mid-career professionals from a wide range of health-related fields, from emergency medicine and health economics to biomedical engineering and research and public health policy. The scholars are an essential part of a major [...]

National Academy of Sciences - USA [to 18 Sep 2021]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 18 Sep 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 18 Sep 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

NIH builds large nationwide study population of tens of thousands to support research on long-term effects of COVID-19

September 15, 2021 — NIH launched the RECOVER Initiative to learn why some people have prolonged symptoms or develop new or returning symptoms after the acute phase of infection from SARS-CoV-2.

PATH [to 18 Sep 2021]

<https://www.path.org/media-center/>

Press Releases

Levis Nderitu joins PATH as first Global Diversity, Equity and Inclusion Director

September 12, 2021 by PATH

PATH is happy to announce that Levis Nderitu is joining PATH as Director, Global Diversity, Equity, and Inclusion. Based in Nairobi, Kenya, Levis will refine the DEI Strategy PATH launched earlier this year and create a DEI center of expertise to advise, support, and bring together global workstreams.

Levis has over 10 years of international development and private sector experience in DEI, culture, and employee engagement across East Africa, Europe, and the United States. Most recently his work at Médecins Sans Frontières in Kenya has included developing a DEI vision and roadmap, serving as an advisor to leadership, facilitating difficult conversations, and training on cross-cultural competence, unconscious bias, and anti-racism...

Sabin Vaccine Institute [to 18 Sep 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 18 Sep 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

17 September 2021

[Forty years of campaigning for equal access to life-saving medicines](#)

15 September 2021

[Community-led projects reach vulnerable populations in Latin America and the Caribbean](#)

14 September 2021

[More than 140 former heads of state and Nobel laureates call on candidates for German chancellor to waive intellectual property rules for COVID vaccines](#)

14 September 2021

[Community-based organizations call for scaled up Internet-based HIV prevention services in China](#)

13 September 2021

[Decline in new HIV infections has stalled](#)

UNHCR Office of the United Nations High Commissioner for Refugees [to 18 Sep 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

[UNHCR warns of dire consequences for refugees from COVID-19 underfunding](#)

17 September 2021 |

[See Milestones above for detail]

UNICEF [to 18 Sep 2021]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

09/17/2021

Schoolchildren worldwide have lost 1.8 trillion hours and counting of in-person learning due to COVID-19 lockdowns, says UNICEF

Urging governments to reopen schools as soon as possible, UNICEF unveils No Time to Lose – a clock counting hours of lost learning – as the UN General Assembly gets underway in NY

Press release

09/15/2021

Indonesia: After 18 months of school closures, children must safely resume face-to-face learning as soon as possible – UNICEF/WHO

Students and teachers will need a full range of support to help catch up on lost learning

Press release

09/14/2021

One month after Haiti earthquake: 260,000 children still need humanitarian assistance - UNICEF

Unitaid [to 18 Sep 2021]

<https://unitaid.org/>

Featured News

15 September 2021

A new initiative will deliver enhanced malaria prevention to children under two across Africa through a WHO-recommended but under-implemented intervention

15 September 2021

Community health workers bring malaria prevention to pregnant women across Africa, and build new entry points to vital services

13 September 2021

Unitaid, the Clinton Health Access Initiative, and Laurus Labs announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children

Vaccine Equity Cooperative [nee Initiative] [to 18 Sep 2021]

<https://vaccineequitycooperative.org/news/>

News

Sep 14, 2021

Media: Community-led efforts are the key to ending this pandemic

This article by Advisory Group member Dr. Alexandre White outlines how community-led responses to vaccination and health care delivery are the solution to the ongoing issues of COVID-19 vaccine access and hesitancy – and

Vaccination Acceptance & Demand Initiative (Sabin) [to 18 Sep 2021]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 18 Sep 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children’s Hospital of Philadelphia [to 18 Sep 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 18 Sep 2021]

<https://wellcome.ac.uk/news>

News and reports

Explainer

Author Josie Golding

How the response to Ebola outbreaks shows why we need to prioritise preparedness

16 September 2021

Explainer

How science is combatting infectious disease

15 September 2021

Explainer

The cost of not preparing for infectious diseases

12 September 2021

The Wistar Institute [to 18 Sep 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 18 Sep 2021]

<https://www.wfpha.org/>

Latest News

In Solidarity with Afghanistan

Sep 14, 2021

Afghanistan is suffering a double burden of disease because communicable diseases are widely prevalent throughout the country and non-communicable diseases are also on the rise. Considering the recent changes in...

World Bank [to 18 Sep 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Infographic: A Policy Package to Promote Literacy for All Children

Date: September 17, 2021 Type: Infographic

World Bank Group to Discontinue Doing Business Report

WASHINGTON, September 16, 2021—The World Bank Group today issued the following statement on the Doing Business report:

“Trust in the research of the World Bank Group is vital. World Bank Group research informs the actions of policymakers, helps countries make better-informed decisions, and allows stakeholders to measure economic and social improvements more accurately. Such research has also been a valuable tool for the private sector, civil society, academia, journalists, and others, broadening understanding of global issues.

“After data irregularities on Doing Business 2018 and 2020 were reported internally in June 2020, World Bank management [paused](#) the next Doing Business report and [initiated](#) a series of [reviews](#) and [audits](#) of the report and its methodology. In addition, because the internal reports raised ethical matters, including the conduct of former Board officials as well as current and/or former Bank staff, management reported the allegations to the Bank’s appropriate internal accountability mechanisms.

“ After reviewing all the information available to date on Doing Business, including the findings of past reviews, audits, and the [report](#) the Bank released today on behalf of the Board of Executive Directors, World Bank Group management has taken the decision to discontinue the Doing Business report. The World Bank Group remains firmly committed to advancing the role of the private sector in development and providing support to governments to design the regulatory environment that supports this. Going forward, we will be working on a new approach to assessing the business and investment climate. We are deeply grateful to the efforts of the many staff members who have worked diligently to advance the business climate agenda, and we look forward to harnessing their energies and abilities in new ways.”

Statement on Release of Investigation into Data Irregularities in Doing Business 2018 and 2020

WASHINGTON, September 16, 2021— WASHINGTON, September 16, 2021—The World Bank Group today released the following statement on behalf of the Bank’s Board of Executive Directors:

“The World Bank’s Board of Executive Directors today authorized the release of “[Investigation of Data Irregularities in Doing Business 2018 and Doing Business 2020 – Investigation Findings and Report to the Board of Executive Directors](#),” an independent external review of the facts and circumstances around previously reported data irregularities in the 2018 and 2020 Doing Business reports.”

Date: September 16, 2021 Type: Statement

[See Milestones above for detail]

International Organizations, Manufacturers Agree to Intensify Cooperation to Deliver COVID-19 Vaccines

Fourth Meeting of the Multilateral Leaders Task Force on Scaling COVID-19 Tools WASHINGTON, 16 September 2021—The heads of the International Monetary Fund, World Bank Group, World Health Organization and...

Date: September 16, 2021 Type: Statement

Climate Change Could Force 216 Million People to Migrate Within Their Own Countries by 2050

Decisive collective action could reduce climate migration by as much as 80 percent WASHINGTON, Sept. 13, 2021—The World Bank's updated Groundswell report released today finds that climate change, an increasingly...

Date: September 13, 2021 Type: Press Release

World Customs Organization – WCO [to 18 Sep 2021]

<http://www.wcoomd.org/>

Latest News – Selected Items

17 September 2021

WCO addresses the Annual Meeting of International Organizations on "Facing Global Crises Together"

On 13 and 14 September 2021, the Organisation for Economic Co-operation and Development (OECD) and the United Nations Commission on International Trade Law (UNCITRAL) hosted online the 8th Annual Meeting of the Partnership for International Organisations. The event brought together 23 Leaders of International Organizations (IOs), including the WCO, represented by its Secretary General, Dr. Kunio Mikuriya, as well as government, academia and civil society representatives to discuss the theme of "Facing Global Crises for Better International Rulemaking" in view of helping governments strengthen, share and improve the international rules that frame our economies, societies and environment...

16 September 2021

The WCO kicks off regional consultations on the next Strategic Plan

World Organisation for Animal Health (OIE) [to 18 Sep 2021]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 18 Sep 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

The fourth South-South Dialogue on LDCs and Development: Reinforcing the multilateral trading system for development

17 September 2021

Keynote address by DG Okonjo-Iweala

Speech

DG Okonjo-Iweala calls on WTO members to deliver tangible outcomes for LDCs at MC12

17 September 2021

Delivering results at the 12th Ministerial Conference (MC12) to enable least-developed countries (LDCs) to become more resilient and more integrated into the global economy is critical for meeting sustainable development goals, Director-General Ngozi Okonjo-Iweala told Geneva-based ambassadors

from LDCs on 16-17 September in Montreux, Switzerland. DG Okonjo-Iweala was speaking at the South-South Dialogue on LDCs and Development sponsored by China.

International organizations, vaccine manufacturers agree to intensify cooperation to deliver COVID-19 vaccines

16 September 2021

The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization met with the CEOs of leading vaccine manufacturing companies to discuss strategies to improve access to COVID-19 vaccines, especially in low— and lower middle-income countries and in Africa. The Task Force expressed concerns that without urgent steps the world is unlikely to achieve the end-2021 target of vaccinating at least 40% of the population in all countries — a critical milestone to end the pandemic and for global economic recovery

[See Milestones above for detail]

.....

ARM [Alliance for Regenerative Medicine] [to 18 Sep 2021]

Press Releases - Alliance for Regenerative Medicine (alliancerm.org)

Selected Press Releases

No new digest content identified.

BIO [to 18 Sep 2021]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 18 Sep 2021]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 18 Sep 2021]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 18 Sep 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

Meet Africa's New Generation of Health Innovators

16 September 2021

IFPMA and Speak Up Africa announce winners of Africa Young Innovators for Health Award

13 September 2021

Report of the Pan-European Commission on Health and Sustainable Development at the WHO EURO 71st

13 September 2021

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are pleased to contribute this statement to the 71st WHO Regional Committee meeting for Europe. EFPIA and IFPMA represent Europe's and the world's leading research-based biopharmaceutical companies, as well as national and regional industry associations, respectively.

COVID-19 has had profound health, social, and economic impacts across Europe and around the world. Coordinated, inclusive, and multi-stakeholder action is the only possible solution to mitigate the devastating consequences of this unprecedented global health emergency.

Innovative health industries remain at the forefront of the global effort to develop and manufacture tests, therapeutics, and vaccines to contain and defeat COVID-19. The existing IP framework has enabled the pharmaceutical industry to respond swiftly to the global crisis and develop several new vaccines with remarkable speed, by engaging in new collaborations to leverage both new approaches and existing molecules.

After more than 200 clinical trials and nearly 300 partnerships and collaborations among manufacturers worldwide, COVID-19 vaccine production has increased exponentially from zero to 5.8 billion doses by the end of August, 20% of which produced in Europe. In Europe 543,129,344 doses have been administered to citizens, equating to around 70% of the population. Globally, the industry is on target to deliver an astounding estimate of 12 billion doses by the end of 2021 – enough doses to vaccinate the world's adult population. That said, COVID-19 vaccines are not equally reaching all priority populations worldwide. Access to COVID-19 related health products is a collective responsibility that calls for global solidarity and coordinated and collaborative action by public and private actors alike. The innovative vaccine manufacturers and biotech companies have supported fair and equitable access to vaccines from the outset of the pandemic, as full and active partners in the ACT-Accelerator.

In this spirit, these companies represented by seven industry bodies, announced in May 2021 the ["Five steps to urgently advance COVID-19 vaccine equity."](#) They commit to working with governments and non-governmental organizations including COVAX, CEPI, and WHO to support stepping up dose sharing, continue efforts to optimize production, call out trade barriers to be eliminated, support country readiness, and continue driving innovation.

Looking to the future, it is important that the world uses the lessons we have learned during the COVID-19 crisis to make sure we are all better prepared and have the capacity to respond to emergent health threats. With the creation of a European Health Emergency and Preparedness Response Authority (HERA), Europe is stepping in the right direction.

We call upon governments to do their part and ensure adequate resources are dedicated to building strong, resilient, and sustainable healthcare systems, supported by WHO EURO and other multilateral organizations, and that health is valued as an investment to ensure growth and prosperity. This would include strengthening prevention, early detection and interception of disease, implementing integrated and patient-centered care models, utilizing digital health and health data to its full potential, and

increasing access to innovation that improves people's health and enhances the efficiency of health systems. We also urge governments to guarantee immediate and unhindered access to pathogens and associated information regarding any COVID-19 variants to support the development of new vaccines and treatments.

Industry is committed to delivering preparedness solutions and to contributing our expertise to relevant discussions with national, regional, and global public health, diseases control and regulatory agencies, and to contribute to resilient and sustainable health systems in partnership with all stakeholders. We look forward to playing a meaningful role in shaping the future so that we are stronger together for the next health emergency.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 18 Sep 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 18 Sep 2021]

<http://www.phrma.org/>

Latest News [Selected]

[America's biopharmaceutical companies to Congress: Government "negotiation" is the wrong approach](#)

September 15, 2021

We agree with leaders in Washington that Americans need help with their health care costs, but these dangerous policy experiments are not the answer.

Blog Post

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 9: E667-756 Sep 2021

<https://journalofethics.ama-assn.org/issue/implantable-material-and-device-regulation>

Implantable Material and Device Regulation

About 10% of Americans will have a device implanted into their bodies during their lifetimes. Fewer than 0.5% of these devices, however, are likely to have been tested in rigorous clinical trials generally regarded as standard by US regulators. Despite looser regulation of materials and devices than for pharmaceuticals, clinician-investigators and the Food and Drug Administration are obligated to balance patient-subjects' safety with demand for patients' timely access to technologies and interventions that might improve or extend their lives. This issue investigates that tension.

[Reviewed earlier]

American Journal of Infection Control

September 2021 Volume 49 Issue 9 p1093-1214

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

September 2021 Volume 61 Issue 3 p311-464

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

August 2021 111(53)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 2 (Aug 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

August 2021 Volume 174, Issue 8

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 298 September 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/298/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 18 Sep 2021)

[No new digest content identified]

BMJ Global Health

September 2021 - Volume 6 - 9

<https://gh.bmj.com/content/6/9>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 18 Sep 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 18 Sep 2021)

[First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report](#)

Cases of immune complex vasculitis have been reported following COVID-19 infections; so far none in association with novel mRNA-based COVID-19 vaccination. This case report describes a cutaneous immune complex...

Authors: Victoria Therese Mücke, Viola Knop, Marcus Maximilian Mücke, Falk Ochsendorf and Stefan Zeuzem

Citation: BMC Infectious Diseases 2021 21:958

Content type: Case report

Published on: 16 September 2021

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 18 Sep 2021)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 18 Sep 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 18 Sep 2021)

[COVID-19 mRNA vaccine and antibody response in lactating women: a prospective cohort study](#)

Immunological protection via breastfeeding is well known. The immunological profile of human milk changes during lactation. No clinical trials have been conducted in lactating women with the newest mRNA vaccin...

Authors: Nadia Charepe, Juliana Gonçalves, A. Margarida Juliano, David G. Lopes, Helena Canhão, Helena Soares and e Fátima Serrano

Citation: BMC Pregnancy and Childbirth 2021 21:632

Content type: Research

Published on: 17 September 2021

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 18 Sep 2021)

[Vaccine hesitancy: evidence from an adverse events following immunization database, and the role of cognitive biases](#)

Vaccine hesitancy has been a growing challenge for public health in recent decades. Among factors contributing to vaccine hesitancy, concerns regarding vaccine safety and Adverse Events (AEs) play the leading ...

Authors: Hossein Azarpanah, Mohsen Farhadloo, Rustam Vahidov and Louise Pilote

Citation: BMC Public Health 2021 21:1686

Content type: Research

Published on: 16 September 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 18 Sep 2021)

[Changes in patients' outlook, behaviors, and attitudes toward COVID-19 after hospitalization and their experiences of discrimination and harassment](#)

This study aims to examine changes in patients' perspectives and outlooks regarding the disease and their health after hospitalization for COVID-19 and investigate their discrimination and harassment experienc...

Authors: Ken Goda, Tsuneaki Kenzaka, Shinsuke Yahata, Ayako Kumabe, Masahiro Katsurada and Hogara Nishisaki

Citation: BMC Research Notes 2021 14:362

Content type: Research note

Published on: 17 September 2021

BMJ Evidence-Based Medicine

August 2021 - Volume 26 - 4

<https://ebm.bmj.com/content/26/4>

[Reviewed earlier]

BMJ Open

September 2021 - Volume 11 - 9

<https://bmjopen.bmj.com/content/11/9>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(8); 2021 Aug 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/386733/>

[Reviewed earlier]

Cell

Sep 16, 2021 Volume 184 Issue 19 p4841-5070

<https://www.cell.com/cell/current>

Reviews

The origins of SARS-CoV-2: A critical review

Edward C. Holmes, et al/

Open Access

A review of the current literature supports a zoonotic origin for SARS-CoV-2 and emphasizes the need to focus on identifying the exact animal host through collaborative and carefully coordinated studies. This will enable the community to understand the roots of the COVID-19 pandemic as well as better prepare us for future pandemics

Articles

Emergence of an early SARS-CoV-2 epidemic in the United States

Mark Zeller, et al.

Genomic and epidemiological analyses provide a clearer picture of one of the earliest SARS-CoV-2 superspreader events in the United States in accelerating transmission, with a single introduction of the virus being responsible for most cases during this period.

Child Care, Health and Development

Volume 47, Issue 5 Pages: 575-731 September 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 3 Pages: 519-825 September 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

June 2021 Volume 43 Issue 6 p917-1134

<http://www.clinicaltherapeutics.com/current>

Commentaries

SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations

Ian D. Wolfe, Sameer J. Patel

Published online: May 06, 2021

e157-e162

Abstract

The use of monoclonal antibodies in children with certain conditions and at high risk for severe COVID-19 has been approved by the US Food and Drug Administration under the Emergency Use Authorization mechanism of the Federal Food, Drug, and Cosmetic Act. No data on the tolerability or efficacy of these therapies in persons <18 years of age are available; there is risk. Whether they will work is unknown, but they could. A disproportionate number of these children who meet the criteria for treatment with mAbs are from communities of black, Native American, and other race. How should health systems, hospitals, and clinicians balance the tensions between being seen as experimenting with an untested drug as opposed to withholding a potentially life-saving treatment? This article identifies, analyzes, and makes recommendations on the methods by which health systems, hospitals, and individual clinicians can ethically balance these tensions.

Exploration and Ethical Analysis of Open-label Pediatric Vaccine Trials in a Pandemic

Ian D. Wolfe, Angira Patel, Larry K. Kocielek, Asma Fazal, Ravi Jhaveri, John D. Lantos

Published online: May 23, 2021

e163-e172

Abstract

Young children will ultimately need to be vaccinated to stop the spread of coronavirus disease 2019 (COVID-19). Initial studies of vaccine were performed in adults. Randomized controlled trials are the gold standard. In the COVID-19 pandemic, many questions need to be answered about the ethics and feasibility of these trials. Given the harms of the COVID-19 pandemic and the now-known efficacy of the vaccines in adults and teens, the question of whether clinical equipoise exists for a placebo-controlled trial of vaccines in younger children remains. Parents may be reluctant to enroll children in these trials because they want their child to receive the vaccine or because they are worried about vaccines or clinical trials in general. One option for gathering data on tolerability and efficacy in children would be to use a nonrandomized trial to enroll parents willing to vaccinate their children and those who are hesitant. We discuss the advantages and disadvantages of such an open-label trial that could provide guidance for future pandemics.

Clinical Trials

Volume 18 Issue 4, August 2021

<https://journals.sagepub.com/toc/ctja/18/4>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 18 Sep 2021]

Sanctioned countries in the global COVID-19 vaccination campaign: the forgotten 70%

Authors: Karl Blanchet, Grégoire Mallard, Erica Moret and Jin Sun

Content type: Commentary

17 September 2021

Abstract

COVAX, the global initiative on COVID-19 vaccines, has set the target of achieving a COVID-19 vaccination coverage of up to 30% of the population of 135 countries in 2 years. Here, we argue that COVAX should anticipate important and unforeseen challenges with regard to sanctioned countries. For those, COVAX needs to provide a higher percentage of the vaccines. Otherwise, the problems of vaccination will linger, risking the advent of new variants and preventing an effective global response in reigning the pandemic under control.

Contemporary Clinical Trials

Volume 108 September 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/108/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 4, Issue 4 / August 2021

<https://www.liebertpub.com/toc/crispr/4/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2021 - Volume 34 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 3 Pages: 97-148 September 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 6, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 45, Issue 4 Pages: 739-995 October 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[New issue; No digest content identified]

EMBO Reports

Volume 22 Issue 9 6 September 2021

<https://www.embopress.org/toc/14693178/current>

Science & Society 4 August 2021 Open Access

[The viral era: New biotechnologies give humans an unprecedented control over Nature and require appropriate safeguards](#)

Bernd Giese

New biotechnologies such as gene drives and engineered viruses herald a viral era that would give humans exceptional power over any organism at the level of the genotype.

Emerging Infectious Diseases

Volume 27, Number 9—September 2021

<http://wwwnc.cdc.gov/eid/>

Expedited Articles

[Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy](#)

A. Baj et al.

Epidemics

Volume 36 September 2021

<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 5 Pages: 1-44 September–October 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

Commentary

Free Access

[A Call for Better, Not Faster, Research Ethics Committee Reviews in the Covid-19 Era](#)

Leonardo Tamariz, Fred J. Hendler, John M. Wells, Annette Anderson, Stephen Bartlett

Pages: 42-44

First Published: 08 September 2021

Ethics & International Affairs

Summer 2021 (35.2) August 2021

<https://www.ethicsandinternationalaffairs.org/2021/spring-2021-35-1/>

The editors of *Ethics & International Affairs* are pleased to present the Summer 2021 issue of the journal! The highlight of this issue is a roundtable organized by Adrian Gallagher on the responsibility to protect in a changing world order. The roundtable contains an introductory essay by Michael Ignatieff and contributions from Adrian Gallagher and Nicholas J. Wheeler; Cristina G. Stefan; Luke Glanville and James Pattison; and Jennifer M. Welsh. Additionally, the issue includes feature articles by Daniele Amoroso and Guglielmo Tamburrini on meaningful human control over weapons systems and Patricia Goff on inclusive trade. It also contains a review essay by Andrea C. Simonelli on climate displacement and justice and book reviews by Reed Bonadonna, Cian O'Driscoll, and Shelley Wilcox.

[Equity and Vaccine Allocation: Beyond Ethics in Prioritization to Equitable Production, Distribution, and Consumption](#)

Nicole Hassoun | July 2021

Conclusion

Ethicists interested in equitable international vaccine allocation have traditionally focused on principles for prioritizing patient populations, but to have the greatest health impact—whether one focuses on lives, life years, or something else—we must change the question. We should ask how we can vaccinate everyone most effectively. We need to address the need for adequate manufacturing and distribution systems, health care workers, funding, trust in science, and community engagement. We must rethink how we support research and development and reward pharmaceutical innovation to fairly address the COVID-19 pandemic and many other major global health problems. Doing so will in the long run protect individuals better than merely shifting resources around as several current proposals for equitable allocation suggest. It is also in the best interest of some of the world's wealthiest countries to help develop basic health systems in countries that lack them and reconsider incentives for new pharmaceutical research and development. We need to foster global solidarity to overcome ongoing pandemics and to prepare for those that will surely come our way. We must do more to ensure that poor countries are not left behind. We should institute basic global health systems and support efforts to research, manufacture, distribute, and help everyone access vaccines and other essential medicines for COVID-19 and other major global health problems.⁵¹ Anything less is inequitable.⁵²

Ethics, Medicine and Public Health

September 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

SUPPLEMENT - Volume 31, Issue Supplement_1, July 2021

https://academic.oup.com/eurpub/issue/31/Supplement_1

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Mental illness represents an enormous personal, social and societal burden for European citizens¹ calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,² and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth'³ and 'm-Health'⁴) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders^{5,6} and meta-analyses show effect sizes similar to face-to-face interventions.⁷

Expert Review of Vaccines

Vol 20 (7) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 18 Sep 2021]

Research Article metrics AWAITING PEER REVIEW

[Integration of HIV and sexual and reproductive health in the era of anti-retroviral-based prevention: findings from assessments in Kenya, Malawi and Zimbabwe](#) [version 1; peer review: awaiting peer review]

Fannie Kachale, Imelda Mahaka, Fatima Mhuriro, Mary Mugambi, Joseph Murungu, Barbra Ncube, Getrude Ncube, Albert Ndwiga, Rose Nyirenda, Violet Otindo, Anna Carter, Megan Dunbar, Janet Fleischman, Jessica Rodrigues, Kate Segal

Peer Reviewers Invited

Funder Bill and Melinda Gates Foundation

PUBLISHED 15 Sep 2021

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 18 Sep 2021]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 2 June 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 18 Sep 2021]

[No new digest content identified]

Global Public Health

Volume 16, Issue 8-9 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

Politics and pandemics

This Special Issue of Global Public Health on Politics & Pandemics brings together 26 articles and commentaries that address diverse aspects of the politics of COVID-19 and related issues. These papers are grouped together in six topical areas: theories and politics of global health, health systems and policies, country responses, social inequalities, social responses, and the politics of science and technology. The goal of the Special Issue is to give readers a sense of the range of topics that have been a focus for research in relation to the COVID-19 pandemic and to provide diverse examples of how research and analysis on the political dimensions of the pandemic can contribute to confronting the COVID-19 crisis.

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 18 Sep 2021]

[The Global Fund: why anti-corruption, transparency and accountability matter](#)

Authors: Zhihao Chang, Violet Rusu and Jillian C. Kohler

Content type: Research

18 September 2021

Background

The creation of the Global Fund to Fight AIDS, Tuberculosis and Malaria, also known as the Global Fund, was prompted by the lack of a timely and effective global response, and the need for financing to fight against three devastating diseases: HIV/AIDS, tuberculosis, and malaria. During the formation of the Global Fund, necessary anti-corruption, transparency, and accountability (ACTA) structures were not put in place to prevent fraud and corruption in its grants, which resulted in the misuse of funds by grant recipients and an eventual loss of donor confidence in 2011. The Global Fund has instituted various ACTA mechanisms to address this misuse of funding and the subsequent loss of donor confidence, and this paper seeks to understand these implementations and their impacts over the past decade, in an effort to probe ACTA more deeply.

De-escalation strategies for non-pharmaceutical interventions following infectious disease outbreaks: a rapid review and a proposed dynamic de-escalation framework

Authors: Charbel El Bcheraoui, Sophie Alice Müller, Eleanor C Vaughan, Andreas Jansen, Robert Cook and Johanna Hanefeld

Content type: Research

16 September 2021

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 3 - July 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 8, October 2021

<https://academic.oup.com/heapol/issue/36/8>

ORIGINAL ARTICLES

The incremental cost of improving immunization coverage in India through the Intensified Mission Indradhanush programme

Susmita Chatterjee, Palash Das, Anita Pinheiro, Pradeep Halder, Arindam Ray ...

Health Policy and Planning, Volume 36, Issue 8, October 2021, Pages 1316–1324,

<https://doi.org/10.1093/heapol/czab053>

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 18 Sep 2021]

[Reviewed earlier]

Human Gene Therapy

Volume 32, Issue 15-16 / August 2021

<https://www.liebertpub.com/toc/hum/32/15-16>

[Reviewed earlier]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

Article Commentary

Likelihood of COVID-19 vaccination by subgroups across the US: post-election trends and disparities

Peter G. Szilagyi, Kyla Thomas, Megha D. Shah, Nathalie Vizueta, Yan Cui, Sitaram Vangala & Arie Kapteyn

Pages: 3262-3267

Published online: 25 Jun 2021

Mini-Review

Landscape and progress of global COVID-19 vaccine development

Hui-Yao Huang, Shu-Hang Wang, Yu Tang, Wei Sheng, Chi-Jian Zuo, Da-Wei Wu, Hong Fang, Qiong Du & Ning Li

Pages: 3276-3280

Published online: 13 Jul 2021

Review

Early approval of COVID-19 vaccines: Pros and cons

Md Arifur Rahman & Md Sayeedul Islam

Pages: 3288-3296

Published online: 20 Jul 2021

Article

[A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 \(SARS-CoV-2\) infection in children](#)

Nilesh Gujar, Muralidhar Tambe, Malangori Parande, Nandkumar Salunke, Ganesh Jagdale, Sarah G. Anderson, Abhijeet Dharmadhikari, Anand Lakhkar & Prasad S. Kulkarni

Pages: 3316-3321

Published online: 15 Jun 2021

Article

[Acceptability of COVID-19 vaccination in Saudi Arabia: A cross-sectional study using a web-based survey](#)

Saeed Mastour Alshahrani, Salem Dehom, Diaa Almutairi, Badr Saud Alnasser, Bandar Alsaif, Ahmed A. Alabdrabalnabi, Abdullah Bin Rahmah, Mastour Safar Alshahrani, Ashraf El-Metwally, Badr F Al-Khateeb, Fatmah Othman & Mohammad Mahtab Alam

Pages: 3338-3347

Published online: 08 Jul 2021

Article

[COVID-19 vaccine hesitancy: a survey in a population highly compliant to common vaccinations](#)

Flora Fedele, Massimo Aria, Valeria Esposito, Maria Micillo, Gaetano Cecere, Maria Spano & Giulio De Marco

Pages: 3348-3354

Published online: 07 Jun 2021

Article

[Factors influencing COVID-19 vaccine hesitancy and acceptance among the Pakistani population](#)

Farooq Ahmad Chaudhary, Basaruddin Ahmad, Muhammad Danial Khalid, Ayesha Fazal, Muhammad Mohsin Javaid & Danial Qasim Butt

Pages: 3365-3370

Published online: 08 Jul 2021

Article

[Quality over quantity: human papillomavirus vaccine information on social media and associations with adult and child vaccination](#)

Annalynn M. Galvin, Ashvita Garg, Jonathan D. Moore, Dana M. Litt & Erika L. Thompson

Pages: 3587-3594

Published online: 04 Jun 2021

Review

[15-year experience with rotavirus vaccination in Mexico: a systematic literature review](#)

Adriana Guzman-Holst, Eduardo Ortega-Barria, Ángel Alexis Flores, Roberto Carreño-Manjarrez, Dagna Constenla & Maria Yolanda Cervantes-Apolinar

Pages: 3623-3637

Published online: 30 Jun 2021

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 18 Sep 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 18 Sep 2021]

[Measuring COVID-19 vaccination coverage: an enhanced age-adjusted two-step floating catchment area model](#)

Authors: Alireza Mohammadi, Abolfazl Mollalo, Robert Bergquist and Behzad Kiani

Content type: Research Article

16 September 2021

International Health

Volume 13, Issue 5, September 2021

<https://academic.oup.com/inthealth/issue/13/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 9 (2021) September 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/80>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 4, August 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

August 2021 Volume 109 p1-324

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

September 14, 2021, Vol 326, No. 10, Pages 889-984

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[Trends in Mortality From COVID-19 and Other Leading Causes of Death Among Latino vs White Individuals in Los Angeles County, 2011-2020](#)

Paul Simon, MD; Alex Ho, MD; Megha D. Shah, MD; et al.

free access has active quiz

JAMA. 2021;326(10):973-974. doi:10.1001/jama.2021.11945

This study compares age-adjusted mortality rates before and during the COVID-19 pandemic (2011-2020) among Latino and White individuals living in Los Angeles County.

Viewpoint

[Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations](#)

G. Owen Schaefer, DPhil; R. J. Leland, PhD; Ezekiel J. Emanuel, MD, PhD

free access

JAMA. 2021;326(10):903-904. doi:10.1001/jama.2021.13226

This Viewpoint highlights countries with higher concentrations of COVID-19–vaccinated residents and excess vaccine supply vs those without, and it emphasizes the clinical and ethical reasons for prioritizing distribution of excess vaccine to underserved countries instead of keeping it for booster administration.

JAMA Network

[COVID-19 Update September 18, 2021](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

September 2021, Vol 175, No. 9, Pages 886-984

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Editorial

[Pediatric COVID-19 Disparities and Prioritizing Equity—Children Are Not Spared](#)

Evida A. Dennis-Heyward, MD, PhD; Snehal N. Shah, MD, MPH

Original Investigation

[Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination RatesA Cluster Randomized Clinical Trial](#)

Peter G. Szilagyi, MD, MPH; Sharon G. Humiston, MD, MPH; Alisa J. Stephens-Shields, PhD; et al.

JAMA Pediatr. 2021;175(9):901-910. doi:10.1001/jamapediatrics.2021.0766

This cluster randomized clinical trial evaluates the effect of online communication training for clinicians on missed opportunities for HPV vaccination rates overall and at well-child care visits and visits for acute or chronic illness and on adolescent HPV vaccination rates.

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England

Defne Saatci, MD; Tom A. Ranger, PhD; Cesar Garriga, PhD; et al.

free access has active quiz

JAMA Pediatr. 2021;175(9):928-938. doi:10.1001/jamapediatrics.2021.1685

This cohort study investigates the association between race and childhood COVID-19 testing and hospital outcomes in children from family practices in England.

JBI Evidence Synthesis

September 2021 - Volume 19 - Issue 9

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

October 2021 Volume 69 Issue 4 p533-682

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[New issue; No digest content identified]

Journal of Community Health

Volume 46, issue 4, August 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-4>

[Reviewed earlier]

Journal of Development Economics

Volume 152 September 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/152/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 3, July 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

August 2021 - Volume 75 - 8

<https://jech.bmj.com/content/75/8>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

Table of Contents

[Violence and COVID-19 across the Globe](#)

Virginia Brennan, PhD, MAEditor, JHCPU

As the summer of 2021 simmers on, JHCPU again publishes a large collection of papers delving into the complex sea of health inequities. In this Note, to stand in for the large array of topics the issue covers, I highlight a small selection, two papers concerning violence, two on COVID-19, and two concerning sub-Saharan African nations...

Journal of Immigrant and Minority Health

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

COVID-2019

Editor's Choice

Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination

Sarah M Bartsch, Patrick T Wedlock, Kelly J O'Shea, Sarah N Cox, Ulrich Strych ...

The Journal of Infectious Diseases, Volume 224, Issue 6, 15 September 2021, Pages 938–948,

<https://doi.org/10.1093/infdis/jiab233>

Our study quantifies the potential value of decreasing vaccine hesitancy, increasing vaccination coverage, and how this may decrease with the time it takes to achieve coverage, emphasizing the need to reach high coverage levels as soon as possible, especially before fall/winter.

Journal of Medical Ethics

September 2021 - Volume 47 - 9

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 3 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

September 2021 Volume 236 p1-336

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 18 Sep 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

September/October 2021 - Volume 27 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 2, June 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-2>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

September 2021 Volume 18 Issue 182

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 6, August 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 95 Number 19 September 2021

<http://jvi.asm.org/content/current> [Reviewed earlier]

The Lancet

Sep 11, 2021 Volume 398 Number 10304 p931-1020, e14

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[Global health has a stake in the upcoming UN Food Systems Summit](#)

Kate R Schneider, Jessica C Fanzo, Lawrence Haddad, Jose Rosero Moncayo

The Lancet Child & Adolescent Health

Oct 2021 Volume 5 Number 10 p681-766, e39-e43

<https://www.thelancet.com/journals/lanchi/issue/current>

Comment

[Citizen science and biomedical research](#)

Dana Mahr, Bruno J Strasser

...Paediatrics, even more than other medical specialties, has long been confronted with the problem that the patient's voice is often mediated through that of their parent or caregiver. It is a characteristic of modern hospital medicine that the complex patient illness narrative has been replaced by a professional description of signs and symptoms, framed in medical categories. But nowadays, online participatory health research projects such as the COVID Symptom Study once again offer the possibility for patients to freely describe how they feel, outside of scientific and medical categories and vocabularies. Such illness narratives can now be processed automatically by analysing word frequency, as in the present paper, although more refined methods relying on artificial intelligence might better preserve the singularity of the individual patient's experience. Finally, as with all participatory initiatives, it is important not just to ask what researchers have gained from such studies, but what was the experience of the people enrolled and whether it matched their expectations. Entering data on a smartphone app is not equivalent to discussing with a paediatrician or health-care worker who can answer further questions and concerns of participants, an especially important factor for underserved communities. In the end, the app has no emotive quality, even if those designing it do. Citizen science

will continue to require a close interaction with professional medical researchers to turn unique illness experiences into research data.

Lancet Digital Health

Sep 2021 Volume 3 Number 9 e534-e611

<https://www.thelancet.com/journals/landig/issue/current>

Review

Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review

Albert T Young, Dominic Amara, Abhishek Bhattacharya, Maria L Wei

Summary

Artificial intelligence (AI) promises to change health care, with some studies showing proof of concept of a provider-level performance in various medical specialties. However, there are many barriers to implementing AI, including patient acceptance and understanding of AI. Patients' attitudes toward AI are not well understood. We systematically reviewed the literature on patient and general public attitudes toward clinical AI (either hypothetical or realised), including quantitative, qualitative, and mixed methods original research articles. We searched biomedical and computational databases from Jan 1, 2000, to Sept 28, 2020, and screened 2590 articles, 23 of which met our inclusion criteria. Studies were heterogeneous regarding the study population, study design, and the field and type of AI under study. Six (26%) studies assessed currently available or soon-to-be available AI tools, whereas 17 (74%) assessed hypothetical or broadly defined AI. The quality of the methods of these studies was mixed, with a frequent issue of selection bias. Overall, patients and the general public conveyed positive attitudes toward AI but had many reservations and preferred human supervision. We summarise our findings in six themes: AI concept, AI acceptability, AI relationship with humans, AI development and implementation, AI strengths and benefits, and AI weaknesses and risks. We suggest guidance for future studies, with the goal of supporting the safe, equitable, and patient-centred implementation of clinical AI.

Lancet Global Health

Oct 2021 Volume 9 Number 10 e1336-e1473

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis

Sachin Silva, et al.

BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial

Judith R Glynn, et al. for the Karonga Prevention Trial Group

Lancet Infectious Diseases

Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

COVID-19 vaccine equity and booster doses

The Lancet Infectious Diseases

The debate on COVID-19 vaccine equity has been long-running, and we have previously weighed in on the topic. However, the facts that (1) by Aug 9, only 12·6 million of the 4·46 billion doses administered globally were in low-income countries, (2) 3·65 billion have been administered in high-income (HICs) and upper-middle-income countries, and (3) WHO Director-General Tedros Adhanom Ghebreyesus actually had to issue a plea for a moratorium on third-dose boosters in HICs on Aug 4, mean that we, again, need to add our voice to the demand for equitable access to vaccines.

“No one is safe until everyone is safe” has become the mantra of the COVID-19 pandemic, with good reason. Unmitigated transmission means rampant viral replication, which in turn means infinite opportunities for the emergence of new, more transmissible variants that could escape natural or vaccine-induced immunity. A perverse social experiment would be to allow the virus to continue ripping through low-income and lower-middle-income countries (LMICs), where people tend to live in close proximity and infection prevention strategies are difficult to implement because much of the populations rely on hand-to-mouth income (India being a case-in-point), while seeing how quickly HICs can redesign vaccines to counter yet another variant that has emerged from LMICs. Beyond the moral argument, this approach would make no economic sense: if many final goods in HICs rely on raw materials and intermediate goods from LMICs, and if LMICs cannot provide these materials because their populations are dying from COVID-19 or are prevented from working because of lockdowns, how long do HICs think that they can keep their own economies running? The RAND corporation estimates that HICs would see a return of US\$4·8 for every \$1 spent on supplying vaccines to LMICs, and the Global Dashboard for Vaccine Equity shows that if vaccine distribution were uniform, HICs still stand to gain the most. Additionally, while HICs hoard their precious vaccines, China and Russia, two ambitious political entities, have been only too happy to offer their vaccines and strengthen their spheres of influence in Africa, South America, southeast Asia, the Middle East, and eastern Europe.

The administration of a third dose is motivated by fear of the B.1.617.2 (delta) variant but the intensity of this fear is unfounded, as there is now evidence that vaccines licensed in HICs are effective enough against it. Conversely, there is no definitive evidence if, and when, a third dose is necessary, and much-needed trials—the only context in which third-dose administration should be acceptable—are eagerly awaited. There is some evidence of waning antibody titres, which is an axiom of any vaccine administration that does not equal waning cellular immunity. Although the world has ubiquitously grappled with the plague of vaccine hesitancy, the level of coverage in HICs and the rates of administration of new doses should now be sufficient to allow the redirection of surplus doses to those who have none via the COVAX initiative. It is deeply ironic that COVID-19 vaccine acceptance might actually be much higher in LMICs than in HICs. A point must also be made about increasingly risky behaviour—it is irresponsible to encourage relaxation of basic physical distancing measures such as mask wearing in public or confined spaces even for vaccinated individuals, which may well be contributing to a large proportion of breakthrough infections.

A crucial problem for getting vaccines to LMICs is an interrupted cold chain. This is the case in Africa, where many communities live without continuous power supplies, and freezers that cost up to \$20 000 are unaffordable. While capacity building is ongoing, countries could focus on donating and administering vector vaccines that are easier to store than mRNA vaccines and are sufficiently safe and effective, particularly in older individuals. Preliminary evidence from the Com-COV trial shows that heterologous vaccination is safe and induces robust immune responses, a viable option for countries that cannot rely on a steady stream of vaccines. There have been calls, reasonable in a time of global catastrophe, to waive intellectual property rights to facilitate local vaccine manufacturing, which should

currently focus on LMICs with sufficiently robust regulatory capacities to ensure the quality of local production, as argued by the [Center for Global Development](#). Vaccine donors and corporations can think about how to help with these issues in the short and long terms.

Vulnerable people in HICs have already been prioritised; vulnerable people in LMICs cannot wait until 2023 for their turn, and this wait is in the best interest of no one.

Articles

[Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study](#)

Paul A Goepfert, et al.

[Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults \(PROTECT\): a randomised, double-blind, phase 3 trial](#)

Timo Vesikari, et al. for the PROTECT Study Group

[Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial](#)

Htay-Htay Han, et al.

[Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance](#)

The Gambia Pneumococcal Surveillance Group,
Grant A Mackenzie, et al.
Open Access

Lancet Public Health

Sep 2021 Volume 6 Number 9 e620-e695

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Aug 2021 Volume 9 Number 8 p803-936, e69-e87

<https://www.thelancet.com/journals/lanres/issue/current>

Articles

[BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers](#)

Yaniv Lustig, et al

Maternal and Child Health Journal

Volume 25, issue 10, October 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-10>

[New issue; No digest content identified]

Medical Decision Making (MDM)

Volume 41 Issue 6, August 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 2 Pages: 329-599 June 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 597 Issue 7876, 16 September 2021

<https://www.nature.com/nature/volumes/597/issues/7875>

Article | 02 August 2021 | Open Access

[Behavioural nudges increase COVID-19 vaccinations](#)

Two randomized controlled trials demonstrate the ability of text-based behavioural 'nudges' to improve the uptake of COVID-19 vaccines, especially when designed to make participants feel ownership over their vaccine dose.

Hengchen Dai, Silvia Saccardo, Daniel M. Croymans

Nature Biotechnology

Volume 39 Issue 9, September 2021

<https://www.nature.com/nbt/volumes/39/issues/9>

Editorial | 09 September 2021

[Sequencing benchmarked](#)

The Sequencing Quality Control 2 (SEQC2/MAQC-IV) project provides resources to aid sequencing reproducibility and highlights factors that can guide platform and software choice.

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 18 Sep 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 9, September 2021

<https://www.nature.com/ng/volumes/53/issues/9>

Comment | 06 September 2021

[FoGS provides a public FAQ repository for social and behavioral genomic discoveries](#)

Here we introduce 'FAQs on Genomic Studies' (FoGS), an open-access repository of explanatory documents that accompany genomic analyses in social and behavioral genomics. For fields such as

social and behavioral genomics that are shaped by an ugly history and uncertain future, socially and ethically responsible research and research communication are crucial. FoGS amplifies one such approach towards responsible research communication.

Daphne Oluwaseun Martschenko, Benjamin W. Domingue, Sam Trejo

Nature Human Behaviour

Volume 5 Issue 8, August 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/8>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 9, September 2021

<https://www.nature.com/nm/volumes/27/issues/9>

Comment | 06 September 2021

Balancing incentives and disincentives for vaccination in a pandemic

Mandates and incentives are being considered to increase uptake of vaccines against COVID-19, but payment for vaccination may be the fairest approach.

Julian Savulescu, Jonathan Pugh, Dominic Wilkinson

Article | 09 July 2021

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

A matched test-negative, case-control study using real-world data from a predominantly working-age population demonstrates efficacy of the mRNA-1273 vaccine to be 100% and 96.4% against the B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants of concern, respectively.

Hiam Chemaitelly, Hadi M. Yassine, Laith J. Abu-Raddad

Article | 13 September 2021

Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

The PfSPZ Vaccine does not protect infants from infection with *Plasmodium falciparum*, the major cause of malaria.

Martina Oneko, Laura C. Steinhardt, Robert A. Seder

Nature Reviews Genetics

Volume 22 Issue 9, September 2021

<https://www.nature.com/nrg/volumes/22/issues/9>

[New issue; No digest content identified]

Nature Reviews Immunology

Volume 21 Issue 9, September 2021

<https://www.nature.com/nri/volumes/21/issues/9>

Comment | 16 July 2021

SARS-CoV-2 and HIV-1 — a tale of two vaccines

It took roughly 1 year for a COVID-19 vaccine to become available, yet, four decades after the first patient with HIV was described, we do not yet have a vaccine for HIV. Here, Barton Haynes examines the biological reasons why vaccine development for HIV is so exceptionally challenging.
Barton F. Haynes

Nature Reviews Drug Discovery

Volume 20 Issue 9, September 2021

<https://www.nature.com/nrd/volumes/20/issues/9>

[New issue; No digest content identified]

New England Journal of Medicine

September 16, 2021 Vol. 385 No. 12

<http://www.nejm.org/toc/nejm/medical-journal>

Original Articles

[**Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting**](#)

[N. Barda and Others](#)

[**Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children**](#)

[P.D. Patel and Others](#)

[**Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine**](#)

[P. Tebas and Others](#)

Editorials

[**The Importance of Context in Covid-19 Vaccine Safety**](#)

[G.M. Lee](#)

[**Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters**](#)

[E.J. Rubin, L.R. Baden, and S. Morrissey](#)

Pediatrics

Vol. 148, Issue 3 1 Sep 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 9, September 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-9>

[Reviewed earlier]

PLoS Biology

August 2021

<https://journals.plos.org/plosbiology/issue>

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 18 Sep 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 18 Sep 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 18 Sep 2021]

[Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria](#)

Angela E. Oyo-Ita, Patrick Hanlon, Ogonna Nwankwo, Xavier Bosch-Capblanch, Dachi Arikpo, Ekperonne Esu, Christian Auer, Martin Meremikwu

Research Article | published 16 Sep 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0257277>

[Acceptance of COVID-19 vaccine in Pakistan among health care workers](#)

Asmara Malik, Jahanzeb Malik, Uzma Ishaq

Research Article | published 15 Sep 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0257237>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 18 Sep 2021]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

September 07, 2021; vol. 118 no. 36

<https://www.pnas.org/content/118/36>

Brief Reports

[Incentives can spur COVID-19 vaccination uptake](#)

Heike Klüver, Felix Hartmann, Macartan Humphreys, Ferdinand Geissler, and Johannes Giesecke

PNAS September 7, 2021 118 (36) e2109543118; <https://doi.org/10.1073/pnas.2109543118>

Prehospital & Disaster Medicine

Volume 36 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 150 September 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/150/suppl/C>

Research article Abstract only

[**The impact of a universal human papilloma virus \(HPV\) vaccination program on lower genital tract dysplasia and genital warts**](#)

M. Clark, N. Jembere, R. Kupets

Article 106641

Research article Full text access

[**Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors**](#)

Qiang Wang, Liuqing Yang, Hui Jin, Leesa Lin

Article 106694

Proceedings of the Royal Society B

29 September 2021 Volume 288 Issue 1959

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 197 Pages A1-A2, e1-e28, 1-82 (August 2021)

<https://www.sciencedirect.com/journal/public-health/vol/197/suppl/C>

Editorial Full text access

[**COVID-19: transferring learning from the pandemic response to non-communicable disease control**](#)

J. Knight, M. Day, A.C.K. Lee, J.R. Morling

Pages A1-A2

Public Health Ethics

Volume 14, Issue 1, April 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 5, September/October 2021

<https://journals.sagepub.com/toc/phrg/136/5>

Research

[Applying the AFIX Quality Improvement Model to Increase Adult Immunization in Wisconsin](#)

Stephanie M. Borchardt, PhD, MPH, [Kailynn Mitchell](#), MPH, [Taylor Larson](#), MPH, [Ellen Ehlers](#), MSW, [Stephanie L. Schauer](#), PhD

First Published February 9, 2021; pp. 603–608

Qualitative Health Research

Volume 31 Issue 8, July 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 3, July 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 18 Sep 2021]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 41, Issue 8 Pages: 1255-1495 August 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 18 Sep 2021]

[No new digest content identified]

Science

Volume 373| Issue 6561| 17 Sep 2021
<https://www.science.org/toc/science/current>

Reports

[Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants](#)

BY Amarendra Pegu et al.

13 Aug 2021: 1372-1377

Open Access

Most individuals vaccinated with mRNA-1273 develop functional antibodies against SARS-CoV-2 variants for at least 6 months.

Research Articles

[Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates](#)

BY Kizzmekia S. Corbett et al.

17 Sep 2021

Open Access

mRNA-1273 vaccine–induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in nonhuman primates.

Science Translational Medicine

Volume 13| Issue 611| 15 Sep 2021

<https://www.science.org/toc/stm/current>

Editorial

[What have we learned from the COVID-19 plague?](#)

Stanley A. Plotkin

15 Sep 2021

FULL ACCESS

The COVID-19 pandemic has been devastating, but it enables us to learn from it and prepare for the next pandemic disease.

Social Science & Medicine

Volume 284 September 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/284/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 18 Sep 2021]

[Process evaluation of complex interventions in chronic and neglected tropical diseases in low- and middle-income countries—a scoping review protocol](#)

The use of process evaluations is a growing area of interest in research groups working on complex interventions. This methodology tries to understand how the intervention was implemented to inform policy and practice. A recent systematic review by Liu et al. on process evaluations of complex interventions addressing non-communicable diseases found few studies in low- and middle- income countries (LMIC) because it was restricted to randomized controlled trials, primary healthcare level and

non-communicable diseases. Yet, LMICs face different barriers to implement interventions in comparison to high-income countries such as limited human resources, access to health care and skills of health workers to treat chronic conditions especially at primary health care level. Therefore, understanding the challenges of interventions for non-communicable diseases and neglected tropical diseases (diseases that affect poor populations and have chronic sequelae) will be important to improve how process evaluation is designed, conducted and used in research projects in LMICs. For these reasons, in comparison to the study of Liu et al., the current study will expand the search strategy to include different study designs, languages and settings.

Authors: María Lazo-Porras, Hueiming Liu, J. Jaime Miranda, Graham Moore, Mafalda Burri, François Chappuis, Pablo Perel and David Beran

Content type: Protocol

Published on: 7 September 2021

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 42 July–August 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/42/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 9 Pages: i-iv, 1015-1138 September 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 36 Pages 5075-5232 (23 August 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/36>

Short communication Full text access

[Parental plans to vaccinate children for COVID-19 in New York city](#)

Chloe A. Teasdale, Luisa N. Borrell, Yanhan Shen, Spencer Kimball, ... Denis Nash

Pages 5082-5086

Short communication Abstract only

[Insurance reimbursements for recombinant zoster vaccine in the private sector](#)

Andrew J. Leidner, Zhaoli Tang, Angela Guo, Tara C. Anderson, Yuping Tsai

Pages 5091-5094

Review article Abstract only

[Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review](#)

R.K. Lucinde, G. Ong'ayo, C. Houlihan, C. Bottomley, ... K.E. Gallagher

Pages 5095-5105

Research article Full text access

Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions

Paul F. Burke, Daniel Masters, Graham Massey

Pages 5116-5128

Research article Full text access

Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization

Benoit Hayman, Maureen Dennehy

Pages 5153-5161

Vaccines

<https://www.mdpi.com/journal/vaccines>

Open Access Review

COVID-19 Vaccine Donations—Vaccine Empathy or Vaccine Diplomacy? A Narrative Literature Review

by [Zhaohui Su](#) et al.

Vaccines 2021, 9(9), 1024; <https://doi.org/10.3390/vaccines9091024> - 15 Sep 2021

Abstract

Introduction: Vaccine inequality inflames the COVID-19 pandemic. Ensuring equitable immunization, vaccine empathy is needed to boost vaccine donations among capable countries. However, damaging narratives built around vaccine donations such as “vaccine diplomacy” could undermine nations’ willingness to donate their vaccines, which, in turn, [...]

Value in Health

September 2021 Volume 24 Issue 9 p1237-1390

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

medRxiv

medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 18 Sep 2021]

Selected Content

A Vaccination Simulator for COVID-19: Effective and Sterilizing Immunization Cases.

Aknur Karabay, Askat Kuzdeuov, Shyryn Ospanova, Michael Lewis, Atakan Huseyin Varol
medRxiv 2021.03.28.21254468; doi: <https://doi.org/10.1101/2021.03.28.21254468> Revision

[The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals](#)

Tawanda Chivese, Joshua Matizanadzo, Omran Musa, George Hindy, Luis Furuya-Kanamori, Nazmul Islam, Rafal Al-Shebly, Rana Shalaby, Mohammad Habibullah, Talal Al-Marwani, Rizeq F Hourani, Ahmed D Nawaz, Mohammad Haider, Mohamed M Emara, Farhan Cyprian, Suhail A. R. Doi
medRxiv 2021.09.03.21263103; doi: <https://doi.org/10.1101/2021.09.03.21263103>

[COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021](#)

Brechje de Gier, Marjolein Kooijman, Jeanet Kemmeren, Nicolette de Keizer, Dave Dongelmans, Senna C.J.L. van Iersel, Jan van de Kasstele, Stijn P. Andeweg, the RIVM COVID-19 epidemiology and surveillance team, Hester E. de Melker, Susan J.M. Hahné, Mirjam J. Knol, Susan van den Hof
medRxiv 2021.09.15.21263613; doi: <https://doi.org/10.1101/2021.09.15.21263613>

[Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study](#)

Paul M McKeigue, David A McAllister, Chris Robertson, Sharon Hutchinson, Stuart McGurnaghan, Diane Stockton, Helen M Colhoun, for the PHS COVID-19 Epidemiology and Research Cell
medRxiv 2021.09.13.21262360; doi: <https://doi.org/10.1101/2021.09.13.21262360>

[Interrogating COVID-19 Vaccine Hesitancy in the Philippines with a Nationwide Open-Access Online Survey](#)

Alexandria Caple, Arnie O. Dimaano, Marc Martin C. Sagolili, April Anne M. Uy, Panjee Mariel G. Aguirre, Dean Lotus C. Alano, Giselle Sophia M. Camaya, Brent John A. Ciriaco, Princess Jerah S. Clavo, Dominic G. Cuyugan, Cleinne Florence Geeseler V. Fermo, Paul Jeremy C. Lanete, Ardwayne Jurel D. La Torre, Thomas Albert T. Loteyro, Raisa Mikaela Lua, Nicole Gayle R. Manansala, Raphael Willard M. Mosquito, Alexa Marie C. Octaviano, Alexandra Erika T. Orfanel, Gheyanna Merly U. Pascual, Aubrey Joy S. Sale, Sophia Lorraine S. Tendenilla, Maria Sofia Lauren R. Trinidad, Nicole Jan S. Trinidad, Daphne Louise V. Verano, Nicanor Austriaco
medRxiv 2021.09.11.21263428; doi: <https://doi.org/10.1101/2021.09.11.21263428>

[Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study](#)

Paul M McKeigue, David A McAllister, Sharon J Hutchinson, Chris Robertson, Diane Stockton, Helen M Colhoun, for the PHS COVID-19 Epidemiology and Research Cell
medRxiv 2021.09.12.21263448; doi: <https://doi.org/10.1101/2021.09.12.21263448>

[Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases](#)

Daniel A.M. Villela, Tatiana Guimarães de Noronha, Leonardo S. Bastos, Antonio G. Pacheco, Oswaldo G Cruz, Luiz Max Carvalho, Claudia Torres Codeço, Marcelo Ferreira da Costa Gomes, Flávio Codeço Coelho, Laís Picinini Freitas, Raquel Martins Lana, Victor Bertollo Gomes Porto, Luiz Antônio Bastos Camacho, Claudio José Struchiner
medRxiv 2021.09.10.21263084; doi: <https://doi.org/10.1101/2021.09.10.21263084>

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccine in Children and Adolescents: A Systematic Review

Meng Lv, Xufei Luo, Quan Shen, Ruobing Lei, Xiao Liu, Enmei Liu, Qiu Li, Yaolong Chen
medRxiv 2021.09.11.21262855; doi: <https://doi.org/10.1101/2021.09.11.21262855>

Predictors of real-world parents' acceptance to vaccinate their children against the COVID-19

Petros Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, Aglaia Katsiroumpa, Ioannis Moisoglou, Daphne Kaitelidou
medRxiv 2021.09.12.21263456; doi: <https://doi.org/10.1101/2021.09.12.21263456>

* * * *

Think Tanks et al

Brookings [to 18 Sep 2021]

<http://www.brookings.edu/>

Up Front

The game is not yet over, and vaccines still matter: Lessons from a study on Israel's COVID-19 vaccination

Oren Heller, Yaniv Shlomo, Yung Chun, Mary Acri, and Michal Grinstein-Weiss

Monday, September 13, 2021

Center for Global Development [to 18 Sep 2021]

<http://www.cgdev.org/page/press-center>

Accessed 18 Sep 2021

[No new digest content identified]

Chatham House [to 18 Sep 2021]

<https://www.chathamhouse.org/>

Accessed 18 Sep 2021

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 18 Sep 2021

Podcast Episode

Dr. LaQuandra S. Nesbitt: "Vaccine Requirements Will Get Us Over The Finish Line"

September 17, 2021 | By J. Stephen Morrison, H. Andrew Schwartz

Blog Post

In Southeast Asia, Privatized Vaccination Schemes Gain Traction

September 16, 2021 | By Simon Tran Hudes

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

September 14, 2021 *News Release*

Preventable Costs of Unvaccinated COVID-19 Patients Rise Sharply in August as Hospitalizations Surge

A surge in COVID-19 hospitalizations among people who have not been vaccinated in August is adding billions of dollars in preventable costs to the nation's health-care system, an updated KFF analysis finds. In August, the new analysis estimates that the preventable costs of treating unvaccinated patients in hospitals total \$3.7...

Rand [to 18 Sep 2021]

<https://www.rand.org/pubs.html>

*Selected Research Reports, Featured Journal Articles
Report*

Identifying Strategies to Boost COVID-19 Vaccine Acceptance in the United States

Sep 9, 2021

This report recommends strategies to help boost COVID-19 vaccine acceptance in the United States in order to reach herd immunity and end the pandemic.

Florian F. Schmitzberger, Kirstin W. Scott, Wilson Nham, Kusum Mathews, Lucy Schulson, Sydney Fouche, Nasma Berri, Alex Shehab, Ashwin Gupta, Rama A. Salhi, Neil Kamdar, Jennifer Bouey, Mahshid Abir

World Economic Forum [to 18 Sep 2021]

<https://agenda.weforum.org/news/>

Media

India Completes First Drone Delivery of Vaccines, Start of New Pilot Programme with World Economic Forum

News 18 Sep 2021

Majority Want to Prioritize Equitable Access to COVID-19 Vaccines Before Boosters

News 10 Sep 2021

- Health experts say at least 60% of world's population needs to be vaccinated by 2022 to get the current pandemic under control – but only 0.4% of doses have been administered in low-income countries
- Majority would receive a booster shot, but think priority goes to people yet to have a full dose
- Read the full report

*	*	*	*
*	*	*	*

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access

publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	